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Resume 
"Les effets de l'activation des recepteurs DP and CRTH2 sur la fonc-
tion des osteoblastes" 
Par 
Mihai Nedelcescu 
Departement de Pharmacologic 
Memoire presente a la Faculte de medecine et des sciences de la sante en vue de 
l'obtention du grade de Maitre en science (M.Sc.) en Pharmacologic, 2010, Universite 
de Sherbrooke, Sherbrooke, Quebec, Canada, J1H 5N4. 
La modulation de PG par l'inhibition ou la stimulation de leur production peut 
etre un facteur a considerer dans la gestion des differentes conditions pathologiques 
osseusses. Sur la base de resultats recents de nos laboratoires ainsi que sur la litera­
ture, nous emettons l'hypothese que la prostaglandine D2 (PGD2) est un important 
agent anabolisant pour les osteoblastes. Nos resultats montrent que la PGD2 diminue 
la proliferation des osteoblastes agissant probablement par 1'intermediaire du recep-
teur CRTH2. Curieusement, alors que le DK-PGD2 (agoniste specifique CRTH2) a ete 
utilise seul ou avec le Naproxene, bien que la proliferation diminue avec la dose, l'effet 
semblait etre restaure au niveau de controle avec les concentrations plus elevees de 
DK-PGD2. Ainsi, nous envisageons l'hypothese de l'existence d'autres mecanismes de 
compensation. La PGD2 n'a pas eu aucun effet utilisee seule ou lorsqu'elle est utilisee 
avec le Naproxene, mais semblait reduire la differenciation osteoblastique lorsqu'elle 
est utilisee avec Diclofenac a une concentration plus elevee seulement. Lorsque la vi-
tamine D a ete ajoute a toutes les conditions, PGD2 a eu un effet inhibiteur sur la 
differenciation (dose-reponse). Lors d'un essai de competition avec PGD2 et des an-
tagonistes DP/CRTH2, le blocage des recepteurs DP n'a pas donne aucun effet, et en 
bloquant le recepteur CRTH2 on a observe une diminution signifiante a une forte 
concentration de PGD2. L'effet est semblable au test fait avec PGD2 et antagoniste 
PPARy ce qui suggere que celui-ci pourrait avoir un role compensatoire qui a renverse 
l'activation du DP. La PGD2 a un effet legerement positif sur la mineralisation des 
osteoblastes, mais pas par le biais de ses recepteurs. Lorsque nous avons utilise la 
PGD2, en presence d'un antagoniste PPARy, la calcification diminue de maniere signi­
ficative, indiquant que l'effet positif de la PGD2 sur la calcification fonctionne plutot a 
travers ce recepteur. 
Mots-clefs: PGD2, osteoblastes, os, recepteurs, prostaglandins. 
Abstract 
"Effects of DP and CRTH2 activation on osteoblast function" 
Modulation of PGs by inhibition or stimulation is a promising approach for 
the management of pain and inflammation in patients with rheumatic disease. Based 
on recent results from our laboratories as well as on the literature, we hypothesise 
that Prostaglandin D2 (PGD2) is an important anabolic agent for osteoblasts. Our re­
sults show that the PGD2 decreases the osteoblasts proliferation acting probably 
through the CRTH2 receptor. Surprisingly, when DK-PGD2 was used alone or with 
Naproxen, although the proliferation decreased with the dose, it seemed to be re­
stored to the control level at higher concentrations of DK-PGD2. Thus, we hypothe­
sise the existence of other compensatory mechanisms. The PGD2 had no relevant ef­
fect alone or when used with Naproxen, but seemed to decrease the osteoblast differ­
entiation when used with Diclofenac at a higher concentration only. When vitamin D 
was added to all conditions, PGD2 had an inhibitoiy effect on the differentiation 
(dose-response), but this could not be replicated when Naproxen was used. In a test 
with Diclofenac, we can assume a decreasing trend-line for differentiation when aug­
menting the PGD2 dose, but the effect is not statistically relevant. In a competition 
test with PGD2 and DP/CRTH2 antagonists, blocking DP receptor yielded no effect on 
differentiation, and blocking the CRTH2 receptor showed a relevant decrease at high 
concentration of PGD2. The effect was similar in a test with PGD2 and PPARy an­
tagonist suggesting that it might have a compensatory, positive effect that reversed 
DP activation. The PGD2 has a slight positive effect on the osteoblast matrix minerali­
sation (with Naproxen), but not through its receptors since use of DP/CRTH2 an­
tagonists did not abrogate this. In a competition test with PGD2 and DP/CRTH2 an­
tagonists we had no response. When we used the PGD2 in the presence of PPARy an­
tagonist, the calcification decreased significantly, indicating that the positive effect of 
PGD2 on calcification works rather through this receptor. 
Keywords: PGD2, osteoblasts, bone, receptors, prostaglandins. 
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1. Introduction 
The bone matrix is continuously regenerated through the process of bone 
turnover when the "old" bone is replaced with "new" functional bone in the remodel­
ling process. The lack of equilibrium between these two processes, the lysis and the 
deposition, is triggering the rheumatic disease. 
Until recently the mainstay in their treatment has been the use of general 
measures without specificity. Such drugs as prednisone and other corticosteroids 
were used in the treatment of most of the diseases to suppress the inflammatory 
process and a usually over-active immune system. The effect was nonspecific and the 
side effects were often life-threatening. 
Prostaglandins (PGs) are active biologic substances that are involved in a wide 
range of physiologic processes and their imbalance could be a factor in pathologies. 
The overproduction of PGs is responsible for pathologic inflammation, trauma and 
injury in rheumatologic and non-rheumatologic diseases. Restoring the PG balance 
could bring back the homeostasis in a more physiological way by acting over signal­
ling mechanisms of the PG receptors as soon as these pathways are deciphered. 
The new therapies include potentially safer (although not more effective with 
pain control) cyclooxygenase-2 specific nonsteroidal anti-inflammatory drugs 
(NSAlDs), leflunomide, tumour necrosis factor (TNF) inhibitors, etanercept and in­
fliximab. 
In this work, we will describe the bone modelling, remodelling, the factors in­
volved, and we will underline the role of the PGD2 receptors on the bone turnover. 
1.1. Bone structure and architecture 
2 
Bone is a specialised connective tissues that serves three important functions 
in the body: 
1. mechanical support in locomotion 
2. protective function of vital organs 
3. metabolic function as a reserve of calcium and phosphate. 
Bones are extremely dense connective tissue that, in various shapes, constitute 
the skeleton. They are the hardest structures in the body, maintaining nevertheless a 
degree of elasticity because of their structure and composition. Hollow tube like, they 
provide great resistance and durability against axial compression forces having at the 
same time a very low weight. The ultimate tensile strength of bone approaches that of 
cast iron, and its capacity to absorb and release energy is twice that of oak, yet the 
weight of bone is only one third that of steel (Martin, 1989; Lee et al., 2002). 
Bone is enclosed, except for the articular regions, in a fibrous outer membrane 
called the periosteum. Periosteum is composed of two layers, an outer fibrous layer and 
a deeper elastic layer containing osteoblasts that are capable of proliferating rapidly 
when a fracture occurs. In the interior of the long bones is a cylindrical cavity filled 
with bone marrow and lined with a membrane composed of highly vascular tissue 
called the endosteum (Sambrook, 2001). 
1.1.1. Macroscopical structure 
At the macroscopic level there are two major types of bone: compact or corti­
cal bone and trabecular or cancellous bone. Cortical bone is located in the diaphyses 
of long bones and on the surfaces of flat bones. There is also a thin cortical shell at the 
epiphyses and metaphyses of long bones. Trabecular bone is limited to the epiphyseal 
and metaphyseal regions of long bones and is present within the cortical coverings in 
the smaller flat and short bones. 
The morphology of cortical and cancellous bone is arranged to accommodate 
the stresses and strains during weight bearing. The functional differences are a conse­
3 
quence of the structural differences (Fig. 1), cortical bone having mainly a mechanical 
and protective function and the trabecular bone a metabolic and mechanical function 
(Marc C. Hochberg, 2003). 
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Fig. 1: Bone macroscopical structure (Alexander Spence, J990). 
1.1.2. Microscopic structure 
Microscopically, bone is made up of two distinct phenotypes: woven and la­
mellar. Woven bone is characteristic of embryonic and foetal development, but it is 
also found in the healthy adult skeleton at ligament and tendon insertions and under 
pathologic conditions. Architecturally, it has an irregular, disorganised pattern of col­
lagen fiber orientation and osteocyte distribution. Mechanical stimulation can cause 
rapid production of woven bone, which ultimately remodels into dense, lamellar bone 
4 
(Rubin et al., 1995), indicating that the woven bone response is a strategic means of 
rapidly responding to changes in functional activity. 
Lamellar or mature bone is found in both cortical and trabecular bone. The 
structural subunits, the lamellae, run parallel to the trabeculae or, as is the case in cor­
tical bone, are arranged in osteons, which are composed of up to 20 concentric lamel­
lar plates forming a cylinder with a diameter of 200-300|im. A central capillary runs 
through the osteon, and up to seven concentric rings of osteocytes are incorporated 
into its wall (Albright J, 1987). 
1.1.3. Bone matrix and minerals 
Calcified bone contains about 25% organic matrix, including cells (2-5%), 5% 
water, and 70% hydroxyapatite [Cai0(PO4)6(OHh]. The osteoid, the freshly synthe-
sised matrix prior to its mineralisation consists primarily of fibers (approximately 
94%) of collagen type 1 oriented in a preferential direction. It is now accepted that the 
backbone of the gene for type 1 collagen is identical in all connective tissues through­
out the body. Therefore, it is most probable that the genetic specificity of the bone 
extracellular matrix resides within the non-collagenous constituents of the tissue. 
These proteins, however, are not spatially isolated within bone but are intimately as­
sociated with the bone collagen, forming a composite structure fulfilling all the bio­
chemical, biomechanical and homeostatic requirements demanded of the bone ma­
trix throughout life (Cowin, 2004). 
The non-collagenous proteins (10% to 15% of the bone protein content), some 
of them unique to bone such as osteocalcin, are embedded in the extracellular matrix 
and may have important signalling functions (bone morphogeneic proteins, growth 
factors, cytokines, adhesion molecules) or play a role during the mineralisation proc­
ess (osteopontin, osteonectin, matrix-gla protein). These highly anionic complexes 
have a high ion-binding capacity and are thought to play an important role in the cal­
cification process. 
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A. Collagen 
The collagen in bone is type 1, which is the same in skin and tendon. Except for 
collagen V, no other forms of collagen are found in the bone matrix. The insoluble fi­
brils of collagen in bone are formed from the individual soluble tropocollagen mole­
cules and are stabilised by intermolecular cross-links derived from aldehyde forms of 
hydroxylysine and lysine. These intermolecular cross-linking compounds of collagen 
are only present in its mature form and are specific for bone and cartilage. Therefore, 
it is believed that they represent a sensitive and specific marker for bone resorption. 
Urinary hydroxyproline, commonly used as marker for bone resorption in the past, is 
not specific to bone (Marc C. Hochberg, 2003). 
B. Non-collagenous proteins 
The proteoglycans consist of a central protein core to which are bound poly­
saccharide chains - glycosaminoglycans - which are strongly polyanionic due to car-
boxyl and sulphate groups. Studies in vitro and histochemical localisation in situ 
showed that proteoglycans are found in close association with collagen fibers and that 
they affect both the rate of fiber growth and the diameter of collagen fibers; it is pos­
sible that they influence the collagen scaffolding (Marc C. Hochberg, 2003). 
C. Bone Gla-containing proteins (BGP) - osteocalcin 
The name osteocalcin derives from the abundance of this protein in osseous 
tissue (10-20% of the non-collagenous protein) and its affinity for Ca2+. Osteocalcin 
has also been called "the vitamin K-dependent protein of bone". Serum osteocalcin 
increases in situations where the bone formation rate is elevated or where bone turn­
over is increased. Osteocalcin binds tightly to hydroxyapatite and is believed to have a 
function in the assembly of mineralised bone, perhaps by participating in the regula­
tion of hydroxyapatite crystal growth. The synthesis of osteocalcin is stimulated sev-
eralfold when 1,25-dihydroxyvitamin D3 is added in osteoblast culture or in vivo (Marc 
C. Hochberg, 2003). 
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D. Sialoproteins 
Two sialoproteins, osteopontin and bone sialoprotein (BSP), previously called 
sialoproteins I and 11, are both cell adhesion molecules, mediating cell attachment of a 
number of cell types in vitro, including bone cells. Both proteins, however, behave dif­
ferently in vitro and probably have a different function in vivo. The synthesis of BSP is 
inhibited by 1,25-dihydroxyvitamin D3, whereas it is stimulated by dexamethasone 
added to the cultured osteoblasts. In contrast, the synthesis of osteopontin by osteo­
blasts is stimulated by 1,25-dihydroxyvitamin D3 (Atkins et al., 2007). 
E. Alkaline phosphatases 
The classic vertebrate alkaline phosphatases are a group of isozymic 
membrane-bound glycoproteins with molecular weights of 100-200 kDa. The wide 
organ and tissue distribution of alkaline phosphatase activity suggests some type of 
generalised function. That this glycoprotein is primarily located in the plasma mem­
brane implies either a carrier or a signal transducer function. Several possible actions 
of alkaline phosphatase in biomineralisation have been proposed: 
• increasing local concentrations of inorganic phosphate (Pi); 
• local destruction of mineral crystal growth inhibitors via expression of 
phosphohydrolase activity; 
• Pi-transporter; 
• Ca-binding protein; 
• Ca-pump (Ca2+-ATPase) in cells or vesicle membranes; 
• regulator of cellular division or differentiation, by acting as a tyrosine-
specific phosphoprotein phosphatase. 
Although there are supportive data for each, no singular function appears to be 
the principal action of the enzyme (Rodan, 1998). 
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F. Bone minerals 
Bone mineral is generically referred to as hydroxyapatite [Cai0(PO4)6(OH)2], a 
plate-like crystal 20-80 nm in length and 2-5 nm thick. Because it is four times smaller 
than naturally occurring apatites and less perfect in structure, it is more reactive and 
soluble and facilitates chemical turnover. The crystals are oriented in the same direc­
tion as the collagen fibers. 
In 10 to 15 days after the organic matrix has been synthesised, the mineralisa­
tion process starts. During the 10 to 15 days, the mineral content increases to 70% of 
its final amount, whereas deposition of the final 30% takes several months. Other gly­
coproteins such as matrix-gla protein and glycosaminoglycans appear to play a role in 
the inhibition of excessive mineralisation (Sommerfeldt & Rubin, 2001). 
1.1.4. Bone cells 
Three distinctly different cell types can be found within bone: the matrix-
producing osteoblast, the tissue-resorbing osteoclast, and the osteocyte, the last ac­
counting for 90% of all cells in the adult skeleton. Osteocytes can be viewed as highly 
specialised and fully differentiated osteoblasts; similarly, osteoblasts have recently 
been described as sophisticated fibroblasts (Huang et al., 2009). Fibroblasts, osteo­
blasts, osteocytes, and adipocytes derive from pluripotent mesenchymal stem cells, 
whereas osteoclasts are of hematopoietic descent and their precursors are located in 
the monocytic fraction of the bone marrow. 
A. Osteoblasts 
Osteoblasts are mono-nucleated cells that originate from mesenchymal stro­
mal cells. Since osteoblasts arise from mesenchymal cells, there are critical develop­
mental mechanisms appropriately activated to control the cell cycle and ensure that 
the phenotype of the osteoblast differs from that of other cells arising from the same 
origin, such as chondrocytes and adipocytes. 
Osteoblasts are recruited to a site of bone formation where they are responsi­
ble for synthesising, secreting, organising, and mineralising the bone matrix, or os-
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teoid. Osteoblasts secrete a variety of other non-collagenous proteins that are incor­
porated into the developing osteoid including fibronectin, biglycan, decorin, and 
galectin (Watkins et al., 2001) (Fig. 2). 
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Fig. 2: Bone cells (Marc C. Hochberg, 2003). 
Morphologically, these cells are cuboidal in shape and located at the bone sur­
face together with their precursors, where they form a tight layer of cells. The plasma 
membrane of the osteoblast is characteristically rich in alkaline phosphatase, whose 
presence in the serum alkaline phosphatase is used as an index of bone formation 
(Marc C. Hochberg, 2003). 
Osteoblasts are highly anchorage dependent and rely on extensive cell-matrix 
and cell-cell contacts via a variety of transmembranous proteins (integrins, connex-
ins, cadherins) and specific receptors (for cytokines, hormones, growth factors) in or­
der to maintain cellular function and responsiveness to metabolic and mechanical 
stimuli (Ferrari et al., 2000; Lecanda et al., 1998). 
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Contributors to osteoblast growth and differentiation include the bone mor-
phogenic proteins, cell growth factors and cytokines (1GF-1, TGF-b, others), hormones 
(PTH, GH, insulin, glucocorticoids, 1,25 (OH)2-vitamin D3), and biomechanical forces 
(Watkins et al., 2001). 
The lifespan of an osteoblast reaches up to 8 weeks in humans (Parfitt et al., 
2000), during which time it lays down 0.5-1.5 pm osteoid per day (Owen, 1972). Glu­
cocorticoid use reduces the osteoblast lifespan, increasing its apoptosis. 
There are four commonly accepted stages in the osteoblast life span: the 
preosteoblast, which demonstrates alkaline phosphatase (ALP) activity and is located 
within bone; the bone matrix protein producer or the mature osteoblast; the osteo-
cyte transformed osteoblast; the post-proliferative osteoblasts or the bone-lining cells. 
B. Osteoclasts 
Osteoclasts are large multi-nucleated bone-resorbing cells that form at skeletal 
sites from the fusion of hemopoietic precursors of the monocyte-macrophage lineage 
that arrive via the circulatory system. The M-CSF stimulation is necessary for the dif­
ferentiation, proliferation and survival of the cells of the macrophage lineage. 
The hemopoietic precursors express also a receptor known as receptor activa­
tor of NFkB (RANK). By activating this receptor, the transcriptional factor NFkB 
translocates to the nucleus and appears responsible for expression of genes that lead 
to the osteoclast phenotype. This receptor interacts with a ligand found on cells of the 
osteoblast/stromal lineage termed osteoclast differentiation factor (ODF, also known 
as RANKL) and with TRANCE (TNF-related activation-induced cytokine). The inter­
action of RANK with ODF keys the generation of the mature and active osteoclast 
(Watkins et al., 2001). A soluble receptor, osteoprotegerin (OPG, which leads to an­
other alias for ODF - OPGL), has been shown to block the ODF/RANK interaction. 
Therefore, the ratio of ODF/OPG is an important regulatory mechanism in bone re­
sorption (Fig. 3). 
The mature osteoclast is a multinucleate cell, containing up to 20 nuclei, stain­
ing for tartrate-resistant acid phosphatase (TRAP). 
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Fig. 3: Differentiation and Activation of Osteoclasts. Exposure of marrow stromal cells and osteo­
blasts to substances such as prostaglandin E2, parathyroid hormone, and 1,25-dihydroxy- vitamin 
D stimulates the expression of osteoclast differentiation factor, a transmembrane protein {Krane, 
2002). 
The main feature of osteoclasts is their ability to resorb fully mineralised bone 
at sites called Howship's lacunae. Both macrophages and osteoclasts are derived from 
hematopoietic stem cells and, similar to macrophages, osteoclasts are highly migra­
tory, multi-nucleated, and polarised cells which carry an arsenal of lysosomal enzymes 
(Teitelbaum, 2000). 
They have to be highly specialised to fulfill their task and possess several 
unique ultrastructural characteristics, such as pleomorphic mitochondria, vacuoles, 
and lysosomes (Walker, 1972). 
An activated osteoclast is able to resorb 200,000 [Jm3/day, an amount of bone 
formed by seven to ten generations of osteoblasts with an average lifespan of 15-20 
days (Albright J, 1987). 
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C. Osteocytes 
Derived from osteoblasts yet distinctly different in morphology and function, 
osteocytes are the most abundant cells in bone. They are smaller in size than osteo­
blasts, contain less cell organelles such as ribosomes and endoplasmatic reticula, and 
have an increased nucleus to cytoplasm ratio. There is a higher number of filopodia, 
or cytoplasmatic extensions, which serve to interconnect the osteocytes and to con­
nect them with the bone-lining cells, creating a three-dimensional syncitium (Curtis et 
al., 1985). Considering that it is osteocytes that are the principal cell in adult bone and 
that neither osteoclasts nor osteoblasts are evident in any significant numbers in a 
skeleton with low turnover, this osteocyte construct may actually orchestrate the spa­
tial and temporal recruitment of the cells that form and resorb bone (Burger & Klein-
Nulend, 1999). 
The osteocytes remain connected with other similar cells but also with bone-
lining cells, inactive osteoblasts (Miller and Jee, 1987) at the bone's surface, creating an 
extensive network of intercellular communication. There is accumulating evidence 
for a functional role of these cellular connections in sensing the need for and direct­
ing the site of new bone formation (Donahue et al., 1995) (Mosley, 2000) .The death of 
osteocytes by apoptosis in oestrogen deficiency, in corticosteroid therapy, in advanc­
ing age, or after damage to bone, is associated with a loss of bone strength before any 
bone loss (Seeman, 2008). 
1.2. Bone modelling 
The bone matrix is secreted by osteoblasts that lie at the surface of the existing 
matrix and deposit fresh layers of bone onto it. Some of the osteoblasts remain free at 
the surface, while others gradually become embedded in their own secretion. This 
freshly formed material (consisting chiefly of type 1 collagen) is called osteoid. It is 
rapidly converted into hard bone matrix by the deposition of calcium phosphate crys­
tals in it. Once imprisoned in hard matrix, the original bone-forming cell, now called 
an osteocyte, has no opportunity to divide, although it continues to secrete further 
matrix in small quantities around itself. Since the networks of osteocytes do not se­
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crete or erode substantial quantities of matrix, they probably play a part in controlling 
the activities of the cells that do. Hence, the first step in remodelling is unlikely to be 
bone resorption. 
Osteoclasts must first be formed and then be told where to go and how much 
bone to resorb. These instructions are likely to arise from signals produced by the de­
formation or death of osteocytes, which define the location and amount of resorption 
needed (Seeman, 2008). While bone matrix is deposited by osteoblasts, it is eroded by 
osteoclasts. The precursor cells are released as monocytes into the bloodstream and 
collect at sites of bone resorption, where they fuse to form the multi-nucleated osteo­
clasts, which then cling to surfaces of the bone matrix and erode it (Fujikawa et al., 
1996). Osteoclasts are capable of tunnelling deep into the substance of compact bone, 
forming cavities that are then invaded by other cells. A blood capillary grows down the 
center of such a tunnel, and the walls of the tunnel become lined with a layer of os­
teoblasts. To produce the plywood-like structure of compact bone, these osteoblasts 
lay down concentric layers of new bone, which gradually fill the cavity, leaving only a 
narrow canal surrounding the new blood vessel. Many of the osteoblasts become 
trapped in the bone matrix and survive as concentric rings of osteocytes. At the same 
time as some tunnels are filling up with bone, others are being bored by osteoclasts, 
cutting through older concentric systems. 
The area causing matrix resorption is composed of three different domains: 
the attachment zone, ruffled border and the remainder. At the contact zone with the 
bone, proton pumps lower the pH to values between 2 and 4, activating the secreted 
enzymes such as tartrate-resistant acid phosphatase (Blair et al., 1989). In the attach­
ment zone, a highly organised actin filament network, form dot-shaped, F-actin rich 
adhesion sites (Akisaka et al., 2006), so-called podosomes (Chabadel et al., 2007) and 
the actin ring (Luxenburg et al., 2006). 
Vacuolar-type proton ATPase (V-ATPase) in osteoclasts is a ruffled border-
associated enzyme responsible for the proton secretion, the acidity being the main 
factor in the Ca solubilisation (Blair et al, 1989; Okumura et al., 2006). The PH on the 
resorbtion pit reaches a value of 2-4, activating the secreted enzymes such as tartrate-
resistant acid phosphatase (Sommerfeldt & Rubin, 2001). This resorptive phase is then 
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followed by a bone formation phase where osteoblasts fill the lacuna with osteoid. 
The latter is subsequently mineralised to form new bone matrix (Sambrook, 2001). 
1.3. Regulation of bone remodelling 
The skeletal system is involved in the body's homeostasis, it is an active system. 
To achieve this, there must be a constant interaction responding to hormones, to the 
physical demand, to stress, to the need of repairing. 
To all these needs, the response is achieved trough the balance of two major 
processes: bone formation and bone resorption, the former controlled by the osteo­
blasts and the latter by osteoclasts. The endocrine, autocrine and paracrine systems 
also have a role in this interplay, acting on the mentioned cells on different stages of 
their development or as conjugated factors of their activities. They add to the roles of 
the bone specific functions like the homeostatic, hematopoietic and mechanical func­
tions. The regulation of bone remodelling is both systemic and local (Hadjidakis & 
Androulakis, 2006). 
1.3.1. Factors acting on osteoblasts and osteoclasts 
Remodelling is a continuous, dynamic activity driven by humoral and biofunc-
tional cues, the result being that about 25% of trabecular bone and about 3% of corti­
cal bone are removed and replaced each year (Parfitt, 1994) (Fig 4). As we age, the bal­
ance between osteoblastic formation and osteoclastic resorption becomes asynchro­
nous: bone loss occurs and results in the clinical disease (Parfitt et al., 1995). 
The plasma concentration of calcium is one of the homeostatic triggers of 
bone remodelling, acting through a feedback mechanism which includes the liver, the 
kidneys and the parathyroid glands. The serum ions of calcium activate the humoral 
system changing the balance for 1,25-dihydroxy vitamin D3, androgen, calcitonin, es­
trogen, glucocorticoids, GH, PTH, and thyroid hormone (Raisz, 1999; Bilezikian et al, 
1996). 
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Fig. 4: Osteoblast action. (A) Osteoblasts and stromal cells produce both macrophage 
colony-stimulating factor (M-CSF) and osteoclast differentiating factor (ODF). In the pres­
ence of permissive concentrations of cellular or soluble M-CSF, binding of ODF to its recep­
tor (RANK) on osteoclast precursor cells results in their differentiation and activation. This 
process is regulated by an inhibitor of ODF, osteoprotegerin (OPG), which competes with 
RANK for binding of ODF to produce an inactive complex. The sites of action of various 
agents used for treating osteoporosis are also shown: SERMS =selective oestrogen-receptor 
modulators. (B) The bone remodeling sequence is initiated by osteoclasts. Subsequently, 
osteoblasts appear within the resorption bay and synthesize matrix, which is mineralized 
later (Philip Sambrook, 2001). 
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The decrease of plasma oestrogen may lead to increased levels of of cytokines, 
1L-1, 1L-6, TNF-a, (Pacifici, 1998) but also can trigger osteocytes apoptosis (Tomkin-
son et al., 1997). An inflammation - local or systemic - could trigger also the release of 
cytokines and limphokines, leading to osteolysis. 
The osteoclasts are formed as a response to several osteotropic factors like 
1,25-dihydroxyvitamin D3 [l,25(OH)2D3], interleukin (lL)-6, PGE2 (Takahashi et al., 
1988) which induce the expression of NFKB ligand (RANKL, a member of the TNF 
family) in osteoblasts. The binding of RANKL to the RANK receptor found on the sur­
face of the osteoclast progenitors (monocytes) activates the osteoclastogenesis. The 
PTH induction of RANKL is conditioned by the presence of cyclooxigenase-2 (COX-2) 
via cAMP production (Okada et al., 2000). The activation of RANKL by the 1L-1,1L-6, 
1L-17 and l,25(OH)2D3 requires the presence of COX-2 as well. (Li et al., 2006). 
The osteoprotegerin (OPG), a soluble "decoy receptor", regulates the RANK 
effect by competing for the same ligand, thus inhibiting the RANK osteolytic effect, 
but it is down-regulated by PTH (Lee & Lorenzo, 1999). These are not the only par­
ticipants involved, different publications mentioning TNF, annexin-11, TGF-£, etc 
(Mundy, 1996; Boyce et al., 1999). 
The damaged area of the bone is signalled by the apoptotic osteocytes to the 
lining cells. The target is confined to minimise the bone loss, creating a Basic Multi­
cellular Unit (BMU) (Hauge et al., 2001). It is possible that the trigger is the collagen 
digestion around the mineralised bone and the exposure of the calcified area. The 
bone lining cells may be responsible for this action as they express collagenase mRNA. 
(Chambers et al., 1985). More than that, Parathyroid hormone (PTH) stimulates colla­
genase production and secretion by osteoblastic cells and it appears to be involved in 
clearing the osteoblast-lining surfaces of the bone to permit access to the osteoclasts 
(Chiusaroli et al., 2003). The PTH binds to the PTH receptor 1 (PTHR1) found on the 
osteoblasts, leading to an increase of RANKL, activating the osteoclastogenesis (Fu et 
al., 2002). Some authors report that PTH acts directly on the osteoclasts receptors, 
although there are not sufficient studies to accustom this theory yet (Dempster et al., 
2005). 
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It is accepted today that the parathyroid hormone (PTH) has dual effect, ana­
bolic and catabolic, depending on the signalling cascade (Datta, et al., 2009) or de­
pending on the way it is administered. Intermittent administration has an anabolic 
effect (Horwitz et al, 2003; Pettway et al., 2005; Pettway et al., 2008), whereas con­
tinuous administration induces bone resorption (Kaji, 2007). 
Calcitonin is a peptide hormone synthesised and secreted by thyroid parafol­
licular C cells. It is regulated by extracellular calcium levels and by gastrointestinal 
hormones such as gastrin. Calcitonin receptors are present on osteoclasts, preosteo-
clasts. The hormone blocks bone resorption probably via mature osteoclasts by en­
hancement of adenylate cyclase and cAMP or as a mitogen acting on bone cells. 
The mechanical load is also a trigger of bone remodelling. The signal is the de­
formation of the bone, followed by the local release of cytokines and also of AA (ara-
chidonic acid) (Cissel et al., 1996) and consecutively of PGE2 leading to the bone re­
sorption in this first step (Rodan, 1998). The bone deposition under the release of an­
drogens and BMPs follows. 
There are many other proposed mechanisms of acting on the bone turnover 
including a bidirectional regulation between osteoclasts and osteoblasts through a 
signalling system (Zhao et al., 2006), and a nervous/neuroendocrine system regulation 
based on leptin. Leptin is a polypeptide hormone that influences body weight, satiety 
and lipid metabolism. It plays a role in the central hypothalamic modulation of bone 
formation, as well as locally within the skeleton, by enhancing differentiation of bone 
marrow stroma into osteoblasts and by inhibiting its differentiation into osteoclasts 
and adipocytes (Ducy et al., 2000) (Takeda et al., 2002) thus proving that the bone re­
modelling is a complex process yet to be discovered. 
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1.4. Eicosanoids and Prostanoids 
Although prostaglandins were the first biologically active eicosanoids to be 
identified, it is now known that the essential fatty acids are converted into a number 
of different types of eicosanoids. Eicosanoid is a term meaning a 20 carbon fatty acid 
derivative. 
Arachidonate and some other 20 carbon polyunsaturated fatty acids give rise 
to eicosanoids, physiologically and pharmacologically active compounds known as 
prostaglandins (PG), thromboxanes (TX), leukotrienes (LT), and lipoxins (LX). Physio­
logically, they are considered to act as local hormones generated in situ, rapidly me­
tabolised, functioning through G-protein-linked receptors to elicit their biochemical 
effects in the immediate vicinity. 
Both von Euler in Sweden and Goldblatt in England discovered marked stimu­
lation of smooth muscle by seminal plasma. Von Euler (1935) then showed that lipid 
extracts of ram vesicular glands contained the activity and this was associated with a 
fatty acid fraction. The factor that showed this effect was named prostaglandin and it 
was thought to possess a variety of physiological and pharmacological properties. The 
name prostaglandin (and the related prostanoic acid structure) derives from the fact 
that early researchers believed that the prostate gland was the site of their synthesis. 
In 1947, Bergstrom started to purify these extracts and soon showed that the 
active principle was associated with a fraction containing unsaturated hydroxy acids. 
In 1956, with the help of an improved test system (smooth muscle stimulation in the 
rabbit duodenum), Bergstrom isolated two prostaglandins in crystalline form (PGEi 
and PGFia). Their structure, as well as that of a number of other prostaglandins, was 
elucidated by a combination of degradative, mass spectrometric, X-ray crystallo­
graphy and NMR studies. The nomenclature is based on the fully saturated 20 carbon 
acid with C8 to C12 closed to form a 5-membered ring, called prostanoic acid. Thus 
PGEi is designated 9-keto-ll a,15 a-dihydroxyprost-13-enoic acid. The 13,14 double 
bond has a trans configuration; all the other double bonds are cis. In the Fig. 6 one can 
see the difference between the 'E', which have a keto group at position 9 and 'F' series, 
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which have a hydroxyl group at the same position; 'a' refers to the stereochemistry of 
the hydroxyl, and the suffix 1, 2 or 3 is related to the number of double bonds con­
tained in the prostaglandin structure (Michael I. Gurr, 2002). 
PGA, PGB and PGC are ketones, PGD and PGE are hydroxyl ketones and PGF 
a is a diol. PG1 has a different structure, given the second ring attached to the cy-
clopentane structure. 
1.4.1 Prostaglandin Synthesis 
Arachidonate (AA) is usually derived from the sn-2 position of glycerophos-
pholipids in the plasma membrane by the action of phospholipase A2 (Fig. 5). It is re­
leased from phosphatidylcholine (PC) and phosphatidylethanolamine (PE) by phos­
pholipase A2, or from phosphatidylinositol (PI) by phospholipase C (PLC) pathway. 
The arachidonate can also come from the diet. AA is the substrate for the synthesis of 
the PG2, TX2 series (prostanoids) by the cyclooxygenase pathway (Fig. 6), or the LT4 
and LX4 series by the lipoxygenase pathway (Fig. 7), with the two pathways competing 
for the arachidonate substrate (Tang et al., 2006). 
The control of the AA release depends mainly of the presence of type IV cyto-
solic PLA2 which can be translocated to the nuclear envelope, endoplasmic reticulum 
(ER) and Golgi apparatus. 
The metabolism of arachidonate substrate by cyclooxygenase pathway gives 
cyclic endoperoxides from which the classical prostaglandins or thromboxanes and 
prostacyclin can be synthesised. A third pathway occurs via cytochrome P450 oxy­
genation where atomic oxygen is introduced leading to fatty acid hydroxylation or 
epoxidation of double bonds. Whereas both the lipoxygenase and cyclooxygenase re­
actions arise from the formation of a fatty acid radical, in P450-oxygenation, activa­
tion of atmospheric molecular oxygen is involved. After this, one oxygen is transferred 
to the fatty acid substrate and one is reduced forming water (Porubsky et al., 2008; 
Moreno, 2009). 
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Besides being the substrate for the eicosanoid synthesis,the arachidonic acid 
has other biological properties, like the modulation of Ca2+ influx and the regulation 
of protein kinase C and phospholipase C. (Lopez-Nicolas et al., 2006; Boittin et al., 
2008). 
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Fig. 5: Biosynthesis of eicosanoids starting from polyunsaturated fatty acids. 
1.4.2. Synthesis enzymes: PGHS 
The key initial reaction in prostaglandin formation is catalysed by the enzyme 
Prostaglandin Endoperoxide Synthase (PGHS). For simplicity this is usually known as 
cyclooxygenase COX (Burdan et al., 2006). 
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There are two major isoforms of the enzyme and crystal structures for both 
have been obtained: PGHS-1 or COX-1 and PGHS-2 or COX-2 (discovered by Daniel L. 
Simmons in 1991). The cyclooxygenases are haemoproteins and they present both cy-
clooxygenase and peroxidase activity (Garavito and Mulichak, 2003). Also, they use a 
variety of substrates like linoleates (a and y) giving rise to different endoperoxides. 
There is a 60% aminoacid homology between the two COX isoforms, but there is a 
difference in localisation, COX-2 acting at the nuclear envelope and COX-1 mainly in 
the ER and close to the cell membrane (Versteeg et al., 1999). 
The product of PGHS is an endoperoxide, subsequently converted to prosta­
glandins D, E and F, to a thromboxane (TXA2) and prostacyclin (PGh). 
Today, we acknowledge the existence of the two isoforms, one with constitu­
tive expression and the other inducible. COX enzymes are integral membrane pro­
teins that sit within one leaflet of the lipid bilayer of intracellular phospholipid mem­
branes of the nuclear envelope and ER. The cyclooxygenase active site is located in a 
channel formed in the center of enzyme, allowing the hydrophobic fatty acid sub­
strate access without leaving the membrane. The peroxidation function is located on 
the outside of the enzyme and appears to be similar in both enzymes. 
It has been proposed that cyclooxygenase COX-1 and COX-2 serve different 
physiologic functions largely because of the striking differences in their tissue expres­
sion and regulation. COX-1 displays the characteristics of a "housekeeping" gene and 
is constitutively expressed in almost all tissues. COX-1 appears to be responsible for 
the production of prostaglandins (PG) that are important for homeostatic functions, 
such as maintaining the integrity of the gastric mucosa, mediating normal platelet 
function, and regulating renal blood flow. In contrast, COX-2 is the product of an 
"immediate-early" gene that is rapidly inducible and tightly regulated. Under basal 
conditions, COX-2 expression is highly restricted; however, COX-2 is dramatically up-
regulated during inflammation. For example, synovial tissues in patients with rheu­
matoid arthritis (RA) express increased levels of COX-2. In vitro experiments on endo­
thelial cells, chondrocytes, osteoblasts, synoviocytes and monocytes/macrophages 
have revealed increased COX-2 expression after stimulation with proinflammatory 
cytokines, such as interleukin 1 (IL-1) and tumour necrosis factor-alpha (TNF-alpha). 
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COX-2 is also increased in some types of human cancers, particularly colon cancer. 
Mechanisms underlying the association between COX-2 over-expression and tu-
mourigenic potential may include resistance to apoptosis (Garavito et al., 2002). 
A PGHS-1 variant, COX-3 (Chandrasekharan et al., 2002) have been under in­
vestigation after its presence has been confirmed at the cartilage level (Gosset et al., 
2006). 
The Prostaglandin Synthase action is the concluding step into the formation of 
a specific prostaglandin. All known PG's have at least one PGS who generates the spe­
cific PG from the PGH2 substrate. 
1.4.3. Prostaglandins - general effects and roles. 
The prostaglandins are involved in modulations of different systems, from the 
CNS (central nervous system) to gastrointestinal (Gl) and immune systems. Moreover, 
they are involved in a plethora of pathological states ranging from inflammation to 
cancer. 
They are considered potent pro-inflammatory mediators and they play an im­
portant role in nociception and pain, since the COX-2 and mPGES-1 (microsomal 
prostaglandin E2 synthase-1) expression are induced in the CNS via the pro­
inflammatory cytokines like 1L-1|3 and TNFcx (Zeilhofer, 2007). They are involved in 
the contraction and the relaxation of the smooth muscles, sleep mechanisms, fever 
induction, renal tubular reabsorption, apoptotic regulation, cell differentiation. 
Fig. 8 presents a general cellular structure activated by possible triggering 
mechanisms like mechanical trauma, inflammation (cytokines). The inducible form of 
Prostaglandin Synthase (COX-2) can also contribute to the increased expression of 
PG's. The synthesised prostaglandins are carried by the prostaglandin transporter 
(PGT) to exert actions on specific receptors. Of course, their action is perhaps ex­
tended to some non-specific receptors - like the nuclear hormone receptor PPAR. 
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Fig. 8: Prostaglandin synthesis and actions in a generic cell. (Funk, 2001). The "X"s show 
the inhibition sites ofCOX-1 and COX-2 with non-specific enzyme blockers (aspirin, ibu-
profen), or specific COX-2 inhibitors (celecoxib). 
Free radicals are generated in the course of PG synthesis, and inhibitors of PG 
synthesis are free radical scavengers. 
Prostaglandins are autacoids with a quick onset of action over the biochemical 
targets. They are not stored, and they have immediate release. Because of their ionic 
structure, PG s do not cross the cell membranes easily, although they are fatty acids 
derivatives. This is why, once their action yielded the wanted cascade of effects, they 
need to be quickly inactivated. Most tissues have the necessary equipment to do so, 
and it is considered that the half-life of the active prostaglandin is less than 5 minutes. 
PGD2, PGE2, PGF2a are eliminated in part through the lungs in a single pass (Ferreira 
& Vane, 1967). 
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Concentrations of major active prostaglandin products in blood are less than 
0.1 nM and because of their rapid catabolism they can only act as local hormones 
modifying biological events close to their sites of synthesis. 
Degradation occurs via 3 and U) oxidation, de-methylation or by oxidation of 
the C-15 hydroxyl group to a ketone by 15-hydroxy-PG dehydrogenase (15-OH-PGDH) 
present in tissues (peroxizomes) (Gosset et al., 2006) (Tai et al., 2002). On the other 
hand, TNF-cx, lL-($ decrease the 15-OH-PGDH mRNA, impeding the keto-
transformation of the PG's, thus prolonging their effects. 
A prostaglandin transporter (PGT), which plays a primary role in mediating 
prostanoid transport and metabolic clearance, has been identified (Chi & Schuster, 
2010). The PGT plays a role in the uptake of newly released prostanoids, thus acting as 
a carrier across the plasma membrane before intracellular oxidation (Chi et al., 2006). 
Moreover, PGT can facilitate intracellular actions of circulating as well as intracellu-
larly produced prostanoids. The PGT preferentially transports PGE2, PGEi, PGF2«, 
PGD2, with high affinity and to a lesser extent, TXB2 and PGI2 (Funk, 2001). 
1.4.4. Prostaglandin receptors. 
There are eight types of the prostanoid receptors (Table 1) conserved in mam­
mals from mouse to human. They are the PGD receptor (DPI), four subtypes of the 
PGE receptor (EP1, EP2, EP3, EP4), the PGF receptor (FP), PG1 receptor (IP) and the 
TXA receptor (TP). They all are G-protein coupled rhodopsin-type receptors with 
seven transmembrane domains, and each is encoded by different genes. In addition, 
there are several splice variants of the EP3, FP, and TP receptors, but they differ only 
in their C-terminal tails. 
For PGD2 there is a distinct type of receptor, chemoattractant receptor-
homologous molecule expressed on T helper type 2 (Th2) cells (CRTH2). This recep­
tor was originally cloned as an orphan receptor expressed in Th2 lymphocytes, and 
has recently been shown to bind PGD2 with an affinity as high as that of DP, although 
the binding profile to other PGD analogs differs from that of DP. The CRTH2 recep-
Class Subtype Agonists Antagonists Signaling 
TXA2 TP U46619, l-BOP, STA2 SQ29548, S-145, Gq, Gs (a), G| (h), z IP3/DAG/Ca2\ zcAMP, 
ramatroban Gh (a), Gi2 AcAMP 
PGD2 DP BW245C, L-644,698, ZK110841 BWA868C,3 S-5751 Gs z cAMP, z Ca2+ 
CRTH2 13,15-Dihydro-15-keto-PGD2, indomethacin, Ramatroban G, A cAMP, Z Ca2t, PLC, 
15-R-methyl-PGD2, 15d-PGJ2 PI3K, MAPK 
PGE2 EP1 ONO-KI-004, iloprost, SC51322, SC51089, ? Z Ca2+ 
17-phenyl-trinor PGE2, sulprostone ONO-8713 
EP2 Butaprost, 11-deoxy PGE1( AH13205, Gs z cAMP, EGFR 
ONO-AEI-259 transactivation, h-catenin 
EP3 Sulprostone, MB28767, misoprostol, ONO-AE3-240, Gj, Gq, Gs A cAMP, z IPj/DAG, z cAMP 
SC46275, ONO-AE-249 L-826266 
EP4 PGEtOH, misoprostol, ONO-AEI-329 AH23848B Gs z cAMP, PI3K, ERK1/2, 
ONO-AE3-2Q8 h-catenin 
PGI2 IP Iloprost, cicaprost, carbacyclin Gs, Gq, Gj z cAMP, z IPj/DAG, A cAMP 
PGF2a FP Fluprostenol, latanoprost Gq z IP3/DAG, Rho, EGFR 
transactivation, h-catenin 
a Partial agonist. 
Table 1: Prostaglandin receptors - signaling (Hata and Breyer, 2004). 
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tor belongs to the family of chemokine receptors, and mediates chemotaxis in Th2 
lymphocytes as well as in eosinophils or basophils (Nagata & Hirai, 2003). 
The IP, DP, EP2, and EP4 receptors mediate a cyclic adenosine monophos­
phate (cAMP) rise and have been termed "relaxant" receptors, whereas the TP, FP, and 
EP1 receptors induce calcium mobilisation and constitute a "contractile" receptor 
group. The EP3 receptor induces a decline in cAMP levels and has been termed the 
"inhibitory" receptor. Also, the prostaglandins bind with the highest affinity to their 
cognate receptor but with lower affinity to other receptors within the family (Breyer 
etal., 2001). 
A. Tromboxane, TP receptors 
TxA2 is a potent stimulator of both platelet aggregation and smooth muscle 
contraction, the latter leading to vasoconstriction. The TxA2 production is implicated 
in the pathogenesis of atherosclerosis and myocardial infarcts. The human TxA2 re-
Fig. 9: TxA2-induced signaling via TP. (A) TxA2 treatment leads to activation of MAP ki­
nase via Gq and PKC.(B) Stimulation of TP by TxA2 leads to a set of cellular signals. 
Adapted after (Bos et al, 2004). 
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ceptor (Fig. 9), designated "TP", was the first eicosanoid receptor cloned (Hirata et al., 
1991). 
B. PGF2« and FP receptors 
PGF2a is generally associated with physiological processes, such as hypertro­
phic cell growth, the induction of interleukin synthesis, luteolysis and uterine con­
traction, plays a critical role in mammalian reproduction, and potentiates mitogenic 
signals and transcriptional activity (Fig. 10). 
Fig. 10. PGF2a-induced signaling via FP. (A) Upon binding ofPGF2a to its receptor, MAP 
kinase activation will generally occur via the activation of the heterotrimeric G-protein Cq, 
leading to the activation of the PKC pathway. PGF201 might also exert its action via Gi. (B) 
Next to MAP kinase activation, stimulation of FP leads to activation of several other sig­
naling proteins, such as PI3 kinase (P13K), p38 MAP kinase, JNK, and p70 S6 kinase. These 
components have been shown to be essential for PGF2<x-mediated physiological events. 
Adapted after (Bos et al, 2004). 
Hypntreplir 
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C. PGEz and EP receptors 
PGE2 induces vasodilatation, is a pro-inflammatory compound, regulates pro­
duction of a variety of cytokines such as TNFa and IL-6, induces relaxation in arterial 
smooth muscle beds, plays a protective role in maintaining the integrity of the gastric 
mucosa, preserves renal blood flow and glomerular filtration rate, controls salt and 
water transport in the distal tubule, stimulates renin release from the juxtaglomerular 
apparatus (Breyer et al., 2001). PGE2 has also been shown to play a role in the mainte­
nance of blood pressure. 
The diverse and sometimes opposing effects of PGE2 may be accounted for in 
part, by the existence of four receptors, designated EP1, EP2, EP3, and EP4, and to the 
heterogeneity in coupling of these receptors to intracellular signal transduction 
pathways (Fig. 11). 
EP2/EP4 
production 
Oq 
production 
Fig. 11: Activation of distinct EPs by PGE2 induces several signaling pathways and cytokine release. 
(A) PCEz binds to distinct EPs to induce either activation of the MAP kinase pathway via Cq or Gi, 
or to induce upregulation ofcAMP and subsequentfy activation of protein kinase A (PKA). The lat­
ter pathway leads to decreased MAP kinase activation. (B) Exposing certain cells to PGE2 results in 
the regulation of cytokine production, such as TNFa, IL-6, and p38 MAP kinase-dependent IL-10 
production. Adapted after (Bos et al, 2004). 
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The EP1 receptor was originally characterised as acting on stimulation of in­
tracellular calcium. Both EP2 and EP4 receptors couple to Gs resulting in stimulation 
of adenylyl cyclase and increased cAMP levels. The EP3 receptor, which couples to a 
Gi-type G protein, has been termed inhibitory.(Muallem et al., 1989) 
D. PGI2 receptors 
Prostacyclin (PGI2) is the primary prostaglandin produced by endothelial cells, 
has vasodilatory and antithrombotic effects, inhibits platelet activation and TXA2-
induced vascular proliferation, has cardioprotective effects, and is an important me­
diator of acute inflammation and inflammatory pain transmission (Crofford, 1997) 
(Fig. 12). 
Fig. 12: Binding of PGh to IP induces cell-specific signaling. PCh induces inhibition of both p42/ 
p44 MAP kinase and p38 MAP kinase via the activation ofGs. In some cell types, IP activation 
triggers the PKC pathway in a Gq-dependent manner. Adapted after (Bos et al, 2004). 
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E. PGDz receptors: DP and CRTH2. PPARy. 
PGD2 is produced in various tissues, and just like PGI2, it inhibits platelet ag­
gregation and causes relaxation of both vascular and non-vascular smooth muscle 
cells. PGD2 has been shown to bind and activate two G-protein-coupled receptors, DP 
and CRHT2 (chemoattractant receptor-homologous molecule expressed on T Helper 
type 2 cells). It is also known as DP2 receptor. 
PGD2-dependent activation of the DP receptor (Fig. 13) mediates various 
physiological events including sleep induction (Cui et al., 2008), cell survival (Gervais 
et al., 2001), and allergic responses (Matsuoka & Narumiya, 2007). 
Fig. 13: PGD2 and PGD2 metabolite-induced signaling. (A) PGD2 normally triggers the Gs-
dependent PKA pathway leading to inhibition of platelet aggregation and muscle relaxation. It 
might also lead to activation of PLC, PKC, and PLD. (B) The PGD2 metabolite lS-d-PGk an­
tagonizes the proinflammatory actions of prostanoids through the activation of the cytoplasmic 
receptor PPARy and independent of PPARy by inhibition of typical inflammatory intracellular 
signaling proteins, such as NF-KB and the STATs. Adapted after (Bos et al, 2004). 
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CRTH2 activation by PGD2 (Fig. 14) can modulate both eosinophil morphology 
and degranulation and can also increase eosinophil and T Helper type 2 cell motility. 
(Gervais et al., 2001; Hirai et al., 2001). 
CRTH2 
• © 
gene 
regulation 
Fig. 14: CRTH2 induced signaling. CRTH2 inhibits adenyfyl cyclase (AQ through Gi proteins; this 
leads to a decrease of intracellular cAMP levels. G0y- subunit complexes released upon Gi activa­
tion directly stimulate phospholipase C0 (PLC0) isoforms, which generate diacylgtycerol (DAG) 
and inositol trisphosphate (IP3) through breakdown of phosphatidylinositol-4,S-bisphosphate 
(P1P2). IP3 mobilizes Ca2* from endoplasmic-reticulum stores. CRTH2 also signals through ar-
restin proteins in a G-protein-independent fashion, which is a newly discovered mode of signaling 
that partly underlies eosinophil shape change after PGD2 challenge. It is possible but not yet 
proven that arrestin recruitment might also lead to G-protein-independent MAP-kinase activa­
tion. (Ulven and Kostenis, 2006). 
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F. PGD2 - Generalities 
The prostaglandin D2 has an important role in the regulation of different body 
functions like sleep regulation, allergic responses, asthma and pregnancy. 
The role of PGD2 in wake-sleep mechanisms has been studied for a long time, 
and published works connected the PGD2 with the non rapid eye movement and sleep 
(Hayaishi, 2002), with pathological states triggered by systemic or infectious diseases 
(Jordan et al., 2004), with narcolepsy (Jordan et al., 2005), and perhaps with more 
complex mechanisms involving melatonine and GABA systems in the brain (Urade & 
Mohri, 2006). 
The PGD2, being released from basophiles and mast cells (Schleimer et al., 
1984), is an important mediator in allergy (Naclerio et al., 1983) having a bronchocon-
strictor effect in allergic asthma (Hardy et al., 1984). This effect is probably regulated 
through the CRTH2 receptor (Boehme et al., 2009a; Boehme et al., 2009b). PGD2 is a 
coronary constrictor in anaphylaxis (Weinerowski et al., 1985) and is a mediator in 
skin dermatitis, probably through CRTH2, (Oiwa et al., 2008). 
The transformation of PGH2 into PGD2 is realised through the catalytic activ­
ity of specific synthetase, called the PGDS, which has two known forms: lipocalin-
type (L-PGDS) and the hematopoietic-type (H-PGDS) (Urade & Eguchi, 2002). 
Cyclopentenone prostaglandins (PGs), such as 15-deoxy-12,13-didehydro-14,15-
didehydro-PGj2 (15d-A<1214)-PDj2), 12,13-didehydro-PGj2 (A12-PGj2), are the products 
resulting from the PGD2 dehydration. The PGJ2 synthesis was initially related to the 
presence of serum albumin (Keelan et al., 2003), but studies showed that the conver­
sion could be done through an albumin-independent mechanism (Shibata et al., 
2002), and through the intermediaries like PGJ2 and 15d-PGD2 to the final compounds 
15d-PGJ2 and A12-PGJ2. 
The biological responses of PGD2 could be in fact the result of the combined 
effects at different levels of the PGD2 and its dehydrated products. The ultimate me­
tabolite of PGD2, 15deoxy-A1214-PGj2, binds specifically to a nuclear receptor, the 
gamma isoform of the peroxisome proliferator-activated receptor (PPARy), thereby 
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promoting adipogenesis (Negishi & Katoh, 2002) and triggering anti-inflammatory 
responses. It also binds to the PGD2 receptors, DPI and CRTH2 (Scher & Pillinger, 
2005). The intranuclear target of the 15d-PGJ2, the PPAR's, are transcription factors 
that regulate gene expression of enzymes associated with lipid homeostasis, inflam­
mation, cell proliferation, and malignancy. The 15d-PGj2 could intervene in other in­
tracellular cascades in a PPAR-independent manner, through a mechanism of covalent 
binding to proteins from the NF-KB system (the IKB kinase-lKK). It blocks the activa­
tion of NF-KB and the extracellular signal-regulated kinase (Erk) signalling pathway 
(Chawla et al., 2001) and also binds to H-Ras and increases cell proliferation (Oliva et 
al., 2003). 
1.5. NSAID's 
Non-steroidal anti-inflammatory drugs - NSAlDs, are drugs with analgesic, 
antipyretic and anti-inflammatory effects. The term "non-steroidal" is used to distin­
guish these drugs from steroids, which have a similar eicosanoid-blocking, anti­
inflammatory action. NSAlDs are non-narcotic. The most prominent members of 
this group of drugs are aspirin, ibuprofen, and naproxen partly because they are avail­
able over-the-counter in many areas. 
Prostaglandins are potent hyperalgesic mediators which modulate multiple 
sites along the nociceptive pathway and enhance both transduction (peripheral sensi­
tising effect) and transmission (central sensitising effect) of nociceptive information. 
Inhibition of the formation of prostaglandins at peripheral and central sites by 
NSAlDs thus leads to the normalisation of the increased pain threshold associated 
with inflammation. 
The structure of the COX proteins consists of three distinct domains: an N-
terminal epidermal growth factor domain, a membrane-binding motif, and a C-
terminal catalytic domain that contains the COX and peroxidase active sites. The 
COX active site lies at the end of a hydrophobic channel that runs from the 
membrane-binding surface of the enzyme into the interior of the molecule (Dann-
hardt & Kiefer, 2001). 
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NSAlDs act at the COX active site in several ways: 
• Aspirin irreversibly inactivates both COX-1 and COX-2 by acetylating an 
active-site serine. This covalent modification interferes with the binding of arachi-
donic acid at the COX active site. 
. By contrast, reversible competitive inhibitors of both COX1 and COX2 iso-
forms (e.g., mefenamate, ibuprofen) compete with arachidonic acid for the COX ac­
tive site. 
• A third class of NSAlDs (e.g., flurbiprofen, indomethacin) causes a slow, 
time-dependent reversible inhibition of COX-1 and COX-2 which results from the 
formation of a salt bridge between the carboxylate of the drug and the arginine 120, 
followed by conformational changes. (Kalgutkar et al., 2000) 
Most of the NSAlDs are non-selective inhibitors acting at the active site of 
both enzymes, COX-1 and COX-2, but selective COX-2 inhibitors have been available 
for use in arthritis public use starting from 1998 (under the U.S. Food and Drug Ad­
ministration approval). Apart from its involvement in inflammatory processes, COX-2 
seems to play a role in angiogenesis, colon cancer and Alzheimer's disease. This is 
based on the fact that it is expressed during these diseases. Lately, acetaminophen is 
believed to act on the COX-3 izoenzyme (Chandrasekharan et al., 2002) decreasing 
fever and pain. Of course, the specificity has a certain degree, interactions could occur 
in a crossover way, the COX-1 inhibitors interacting with the COX-2 sites (Hinz et al., 
2006). Studies have shown that the use of NSAlDs is associated with a reduced inci­
dence of colon cancer (COX-2) and a reduced risk of Alzheimer development (COX-2). 
The NSAlDs have an important role in controlling pain associated with rheumatoid 
arthritis (Simmons et al., 2004). 
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1.6. Prostaglandins and bone 
Prostaglandins have multiple effects on bone cells, and sometimes opposite 
effects in different species. Their role is therefore difficult to discern. They are power­
ful bone and cartilage resorbing agents in certain in vitro studies, yet they are potent 
anabolic (bone forming) agents when administered in vivo. Experimental investiga­
tions proved their influence on inflammatory processes, and, above all, on the bone 
destruction in the pathogenesis of rheumatoid arthritis and osteomyelitis. 
Prostaglandins very probably induce the local intercellular communication and 
regulate the metabolism of bone and cartilage. They are supposed to be local media­
tors of mechanical stress, electric phenomena, as well as of hormonal control mecha­
nisms in cytobiologic and cytochemical reactions within the skeletal system. 
Prostanoids produced by bone include PGE2, PGF2a, and 6-keto-PGFia, the 
metabolite of PGI2, as well as PGD2 and thromboxane. 
The first thing worth mentioning is the involvement of dietary fatty acids into 
the bone metabolism. The poly-unsaturated fatty acids (PUFA, n-6 and n-3) seem to 
modulate hOB metabolism by influencing the OPG/RANKL system responsible for 
the PGE2 interactions (Coetzee et al., 2007). 
Osteoblasts and osteoclasts, the most important contributors to bone remod­
elling, produce PGs, which are shown to modulate the cell function in normal bone 
metabolism and in bone healing (Gajraj, 2003). Several receptors have a proven exis­
tence on the hOB (Sarrazin et al., 2001), and the hOB themselves produce these auta-
coids (Hackett et al., 2006). Moreover, in fluids containing albumin, PGE2 and PGD2 
are slowly dehydrated within the cyclopentane ring to the cyclopentenone prosta­
glandins PGA2 and PGJ2, respectively. PGJ2 is metabolised further to yield 15-deoxy-
A12-14 PG]2 (15d-PGj2). The cyclopentenone PGs, which are not thought to act via the 
classical PG receptors, are active when given exogenously and can have opposite ef­
fects from some of the primary PGs (Negishi & Katoh, 2002). 
The PGE2 is the most abundant PG produced by the OB, producing through 
the EP2 and EP4 receptors, either anabolic or catabolic effects on the bone (Fig. 15). A 
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large number of cytokines, hormones and growth factors control the PGE2 produc­
tion: IL-1, 1L-6 which lead to bone resorbtion (Kwan Tat et al., 2004), 1L-4 and 1L-3 
which suppress the PGE2 production and inhibit the bone resorbtion (Onoe et al., 
1996). Fresh serum is a potent stimulator of COX-2 expression and PGE2 production 
in cultured osteoblastic MC3T3-E1 cells (Pilbeam et al., 1995). The same effect is ob­
tained with selective agonists for IP, TP, FP and DP receptors (Sakuma et al., 2004). 
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Fig. 15: Possible effects of dietary lipids on the bone. AA: arachidonic acid; CLA: conjugated lino-
leic acid; EPA: eicosapentaenoic acid; lGF/IGFB:insulin-like growth factors/IGF binding pro­
teins. (Watkins et al, 2001). 
Systemic administration of PGE2 induces bone formation and increases bone 
mass (Marks & Miller, 1988), it increases the blood flow and callus formation in rabbits 
by inhibiting osteoclastogenesis (Mano et al., 2000) and by increasing the AlkP ex­
pression (Kakita et al., 2004). It can also have a catabolic effect leading to bone resorb­
tion (Suzawa et al., 2000). As a confirmation of the opposite roles of the PGE2, we 
mention that it can be made active by Bone Morphogenetic Protein 2 (BMP-2) which 
acts as a bone repair factor and normally increases bone formation. It can also induce 
osteoclastogenesis in mice (Blackwell et al., 2009). 
Both PGD2 receptors, the DP and the CHRT2, are present on the hOB (Gallant 
et al., 2007). By transduction signals through these receptors, the PGD2 induces calci­
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fication (possible by its metabolite, 15d-PGj2) (Koshihara & Kawamura, 1989) and has 
probable proliferative (Tsushita et al., 1992) or indirect anti-proliferative properties 
(Haberl et al., 1998). In human primary OB, PGD2 activates the DP receptor thereby 
decreasing the osteoprotegerin expression, but in the same cells, through the CRTH2 
receptor, it decreases the RANKL production. The production of PGD2 is stimulated 
by TNF-a, 1L-1, PTH, VEGF (Gallant et al., 2005) and also by mechanical strain (per­
haps through the system of A12 PGJ2/PPAR) (Siddhivarn et al., 2006). 
The PGD2 has anabolic or catabolic effects on the bone, carrying a controver­
sial role in bone homeostasis. PGD2 stimulates calcification of hOB (Koshihara & Ka­
wamura, 1989) and has proliferative effects (Tsushita et al., 1992) or anti-proliferative 
effects through its metabolites (Haberl et al., 1998). PGD2 stimulates the osteoclasto-
genesis (via 1L-6) (Durand et al., 2008; H. Tokudaa, 1999) probably by inhibiting the 
OPG production (Samadfam et al., 2006). 
The PG1 receptor, IP, has been identified also on the cultured hOB (Fortier et 
al., 2001), (Sarrazin et al., 2001) and its proven role seems to be inducing the expres­
sion of COX-2 enzyme (Sakuma et al., 2004). 
The TP and FP receptors presence on human osteoblasts have been also 
proven (Sarrazin et al., 2001) (Samadfam et al., 2006). The FP acts as an inducer of 
COX-2 on rodent cloned osteoblastic cells, inhibits the collagen synthesis (Pilbeam et 
al., 1995) and increase the OPG accumulation on MG-63 cells, but not on hOB (Sa­
madfam et al., 2006). 
1.7. Bone pathology 
The bone pathologies are the diseases resulting from disorders of bone forma­
tion and/or resorption, by changing the rates of bone turnover. These include the 
metabolic bone disease and those related to cancer and inflammatory processes. 
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1.7.1. Osteoporosis 
Osteoporosis is the most common metabolic bone disease. Osteoporosis was 
defined as "a disease characterised by low bone mass and micro-architectural deterio­
ration of bone tissue, leading to enhanced fragility and a consequent increase in frac­
ture incidence" (1993, Am ] Med, 94, 646-50). The disease is diagnosed when the bone 
mineral density is 2.5 standard deviations below the young adult mean. A bone min­
eral density between 1 and 2.5 standard deviations below the young adult mean is 
termed "osteopenia". 
In Canada, 1 in 4 women and 1 in 8 men have osteoporosis (Brown & Josse, 
2002); 54% of postmenopausal women in the United States have osteopenia and an­
other 30% have osteoporosis. 
It has been estimated that bone mass reaches a peak about 10 years after linear 
growth stops. Peak mineral density is lower in women, especially Caucasian women as 
compared to black women and men. Women can expect to lose 35% of cortical and 
50% of trabecular bone with age. Men can expect to lose about two-thirds of these 
values. In women, about half the loss can be ascribed to menopause (Serhan, 2004; 
Giguere & Rousseau, 2000; Brown & Josse, 2002). 
Cellular changes Probable culprits 
Sex steroid deficiency t Osteohistogenesis 
tOsteoclastogenesis8 
t Life-span of osteoclasts 
J Life-span of osteoblasts 
1 Life-span of osteocytes 
JOsteoblastogenesisP 
JOsteoclastogenesis 
tAdipogenesis 
i Life-span of osteocytes 
j Osteohistogenesis 
TOsteoclastogenesis0 
tAdipogenesis 
I Life-span of osteoblasts 
J Life-span of osteocytes 
Increased IL-6, TNF, IL-1 Rl/IL-RII 
MCSF; decreased TGF-|3; OPG 
Loss of proapoptotic and antiapoptotic 
effects of sex steroids, respectively 
Senescence Increased PPARy2, pgJ2, noggin; 
decreased IL-11, IGFs 
Glucocorticoid excess Decreased Cbfal and TGF-p R1; 
and BMP-2 and IGF1 action 
Increased PPARy2 
Decreased Bcl-2/BAX ratio 
aOversupply of osteoclasts relative to the need for remodeling. 
bUndersupply of osteoblasts relative to the needs for cavity repair. 
cOsteoclastogenesis may increase transiently at the early stages of steroid therapy, but decreases subsequently. 
Table 2: Cellular Changes and Their Culprits in the Three Most Common Types of Osteoporosis. 
(George C.Tsokos, 2000). 
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There are many factors that influence the bone mass loss leading to osteoporo­
sis: genetic background (Albagha & Ralston, 2006), the lifestyle (Lock et al., 2006), low 
estrogen levels (Amin et al., 2006), calcium and vitamin D deficiency (Lips, 2001) (Ta­
ble 2.). 
The accumulation of adipocytes in bone marrow is often observed in patients 
who manifest bone diseases such as osteoporosis, showing a lack of balance between 
the osteoblastogenesis and adipogenesis (Nishimura et al., 2007) (Fig. 16). 
Fig. 16: "Fatty bone" - Femoral head presenting rough (destroyed) articular surface and large, 
spongiform trabeculae filled with fat. 54 years old male patient. 
1.7.2. Rickets and Osteomalacia 
Rickets and osteomalacia are characterised by a defect of mineralisation due to 
calcium and phosphate deficiencies. This could be due to inadequate absorption by 
the gastrointestinal tract, lack of sunlight exposure or disorders of vitamin D metabo­
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lism, increased renal excretion, increased catabolism, or drug induced (e.g., fluoride, 
etidronate). The lack of vitamin D results in a fall of serum calcium concentration and 
bone mineralisation becomes defective. Rickets is a disease of the growing skeleton 
and affects the epiphyseal plate and bones of children. Osteomalacia is the adult 
counterpart. 
The characteristic histological feature of rickets and osteomalacia is deficiency 
or lack of mineralisation of the organic matrix of bone accompanied by low values for 
serum calcium and phosphorus. Osteomalacia is defined as excess osteoid (hyperos-
teoidosis) and a defective bone matrix mineralisation and this is why the biochemical 
markers associated with increased osteoid production, such as bone-specific alkaline 
phosphatase and osteocalcin, will be elevated in states of rickets and osteomalacia 
(Cole et al,, 1985). 
The disease has proven hereditary causes (Nguyen et al., 2006), but can be trig­
gered by a osteosarcoma or by mesenchymal tumours (Folpe et al., 2004), posing 
problems for the differential diagnostics. 
1.7.3. Osteopetrosis 
Osteopetrosis results from a reduction in bone resorption relative to bone 
formation, leading to an accumulation of excessive amounts of bone. The relative de­
crease in resorption is a consequence of inadequate osteoclastic bone resorption. Al­
though the osteoclasts are unable to resorb the bone being incapable of acidifying 
their ruffled border, they continue to stimulate the osteoblasts, leading to an increase 
in bone mass (Karsdal et al., 2007). There are three major categories of the disease 
(malignant, intermediate, and mild) with a variety of subtypes. 
1.7.4. Hypophosphatasia 
Hypophosphatasia (HPP) has been reported throughout the world and seems 
to affect all races (Whyte et al., 1986). However, it is especially prevalent in Mennon-
ites in Manitoba, Canada, where about 1 in 25 individuals is a carrier, and 1 in 2500 
newborns manifests severe disease (Greenberg et al., 1993). In HPP, circulating levels 
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of calcium and inorganic phosphate are usually normal or elevated, yet the skeleton 
does not mineralise properly, thus showing the role of AlkP in biomineralisation 
(Whyte et al., 1995; Anderson et al., 1997; Whyte et al., 2000). 
1.7.5. Paget's Disease 
Paget's disease or Osteitis Deformans, named after James Paget, (1814-1899) is a 
localised disorder of bone, with increased bone remodelling, bone hypertrophy, and 
abnormal structure. It is seen in patients living above their fourth decade, but has a 
slight male predominance. It is common among the white population of England, 
France, Austria, Germany, Australia, New Zealand, and the United States (with an es­
timated incidence of 3%). It is rare in Scandinavia, China, Japan, and Africa (Gomez et 
al., 2001). 
The majority of patients are without symptoms. When symptoms are present, 
skeletal deformity and pain are most common. Deformities are usually most apparent 
in the skull, face, and lower extremities. Bone fragility and disorganisation of the ma­
trix result from the accelerated bone turnover yielding increased levels of bone mark­
ers including serum alkaline phosphatase, osteocalcin, and the propeptide of type 1 
collagen. Bone is brittle in spite of the increase in bone density and size. Secondary 
malignancies have been described in long-standing Paget disease, the commonest of 
which is osteosarcoma (Singer, 2009). 
1.7.6. Rheumatoid arthritis 
RA is considered to be an autoimmune disease that may involve multiple organ 
systems. Joint involvement predominates in most patients. The disease occurs more 
often in women than men in a ratio of about 3:1. It may appear at any time during life 
but has its peak incidence between 35 and 50 years of age (David M. Reid, 2008). 
RA is an illness that affects much more than just the joints, but the joint struc­
ture, including the synovium and the bone and periarticular muscles. Systemic symp­
toms are common (Abramson & Yazici, 2006). Symptoms often start gradually, over 
months. Patients often experience difficulty in pinning down exactly when their ill­
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ness started. The first symptoms are often vague and include fatigue, lack of energy, 
feeling depressed or washed out, and stiffness in the morning that lasts longer than 30 
minutes. 
A variety of predispositions are recognised for individuals with RA, including 
genetical and environmental factors, age, gender, trauma and exercise (Yoshitomi & 
Sakaguchi, 2005). 
1.7.7. Cancers 
The bone marrow is one of the more common organs to be involved by tu­
mours that metastasise via the bloodstream. In adults the tumours most often seen 
are carcinomas of the prostate gland, breast and lung, although any tumour that 
causes blood-borne metastases may infiltrate the marrow (Ingle et al., 1978). 
Fig. 17: Fracture on pathological bone. Bone osteolitic metastasis following a diagnosed 
breast cancer (25years before). Woman, aged 51. By courtesy ofM.D. E. Nedelcescu. 
Infiltration of the marrow may be suspected on the basis of the following: (i) 
bone pain; (ii) pathological fractures, lytic lesions (Fig. 17) or sclerotic lesions demon­
strated radiologically; (iii) unexplained 'hot spots' on isotopic bone scans or positron 
emission tomography (PET) scanning; (iv) an abnormal magnetic resonance imaging 
scan; (v) hypercalcaemia or elevated serum alkaline phosphatase activity; or (vi) unex­
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plained haematological abnormalities (Anner & Drewinko, 1977; Syed et al., 2007). Os­
teosarcomas (also known as osteogenic sarcoma) are malignant neoplasms of bone 
that are composed of proliferating cells that produce osteoid. Osteosarcomas appear 
in Paget's disease, but with an occurrence of less than 1% (Singer, 2009). 
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Rationale 
A survey of the literature has shown that stimulation of human OB by PGD2 
induces an increase in collagen type 1 synthesis and matrix mineralisation but the re­
ceptor subtypes responsible for these actions were not described (Tasaki et al., 1991). 
Studies performed in our laboratory showed that the major prostaglandin re­
ceptors exist at human osteoblasts level (Sarrazin et al., 2001). The osteoblasts pro­
duce the PGD2 through the lipocalin-type PGD2 synthase (L-PGDS) and both PGD2 
receptors, the DP and CRTH2, are present on cultured cells (Gallant et al., 2005). 
These results support our working hypothesis that PGD2 may act as an auto­
crine or paracrine agent in bone and have a positive impact on bone anabolism. 
Other reasons that make PGD2 an interesting possible pharmacological target is the 
existence of two receptors mediating its actions, thus allowing more specific and less 
side effect-prone pharmacological targeting. 
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Objectives 
In the present study we complete and extend the initial observations from our 
laboratory and test our hypothesis using human bone cells in culture. Our specific 
objective is to determine the roles of DP and CRTH2 on the control of osteoblast me­
tabolism, by using the PGD2 and specific DP and CRTH2 agonists and antagonists, 
and evaluate the following parameters: proliferation by incorporation of [3H]thymid-
ine, cell differentiation (expression of differentiation markers) and mineralisation. 
11. Materials and methods 
11.1. Materials 
The fetal bovine serum (FBS) were purchased from Gibco BRL (Rockville, MD, 
USA). Dulbecco's Modified Eagle's Medium (DMEM) came from Sigma-Aldrich Ltd. 
Compounds BW 245C, BW A868C, PGD2 and 13,14-dihydro-15-keto PGD2 (DK-PGD2), 
T0070907, CAY 10471 were from Cayman Chemical Co. Compounds were dissolved 
in dimethyl sulfoxide or ethanol and the solvents were kept at less than 0.1% in the 
final solutions. Penicillin/streptomycin, L-ascorbate, amphotericin, trypsin, and 1,25-
dihydroxyvitamin D3 [l,25(OH)2D3] were purchased from Sigma (St. Louis, MO, USA). 
[3H]Thymidine, and the Alkaline Phosphatase Substrate Kit were purchased from Bio-
Rad Laboratories (2000 Alfred Nobel Drive, Hercules, CA 94553). The calcium Quan 
tiChrom assay kit was purchased from BioAssay Systems (Hayward, CA, USA). All 
other reagents used were of high-grade quality. 
11.2. Cell culture 
Specimens of human trabecular bone were obtained from patients undergoing 
total hip arthroplasty. In conformity with Quebec's civil law, each patient signed an 
informed consent. hOBs were cultured from these tissues following a previously re­
ported method with minor modifications (Sarrazin et al., 2001). Briefly, thin slices of 
trabecular bone were treated with 2.5 mg/ml of trypsin in phosphate-buffered saline 
(PBS) for 1 h at 37°C, washed extensively in PBS, and cut into fragments of approxi­
mately 2 mm2. Fragments were seeded in 100-mm culture dishes containing 10 ml 
DMEM supplemented with 10% FBS, 50 U/ml of penicillin, 150 |ig/ml of streptomycin, 
2.5 (ig/ml of amphotericin, 2.2 mg/ml of sodium bicarbonate, and 50 |ig/ml of L-
ascorbate. The plates were incubated at 37°C in a 5% CO2 atmosphere. The culture 
medium was replaced at 3-to 4-day intervals. After reaching confluence (4-5 weeks), 
cells were trypsinized (0.1%trypsin in PBS) and subcultured at a ratio of 20,000 cells/ 
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cm2 in 100-mm culture dishes. First-passage cells were grown to confluence, incu­
bated 24 h in DMEM containing 0.2% FBS, and used in the experiments. These cells 
have been shown previously to exhibit phenotypic characteristics of osteoblasts such 
as response to parathyroid hormone (PTH) and production of alkaline phosphatase 
and osteocalcin. 
11.3. Cell proliferation 
Osteoblast proliferation was studied by measuring [3H]thymidine (2 (aCi/ml) 
incorporation into trichloroacetic acid (TCA)-insoluble material. Briefly, cells were 
plated at a density of 30,000 cells/well (15,000/cm2) in 24-well plates and cultured for 
24h in DMEM complete medium, in the presence of [3H]thymidine. 24 h later, the 
plates were washed with cold PBS two times followed by washing with a 10% TCA 
cold solution. After fixation with 50 pi of EtOH/Ether (3:1) they were left to dry at 
room temperature for at least 2 hours. 
Incorporated [3H]thymidine was released through washing with 600^1 of 0.2N 
of NaOH after 30 minutes wait time followed by trituration. A 500pl collected vol­
ume for each well was supplemented with 50 pi of acetic acid (glacial) and 5 ml of scin­
tillation liquid. The radioactivity was measured using a ^-scintillation counter. Results 
are expressed as counts per minute of triplicates. 
11.4. Measurement of alkaline phosphatase activity 
Alkaline phosphatase was used as a marker of osteoblast differentiation and 
was measured in disrupted cells using p-nitrophenyl phosphate as substrate. Briefly, 
cells were seeded at a density of 120,000 cells/well (60,000/cm2) in 24-well plates left 
to adhere for 24h and then cultured in the presence of 10 nM of l,25(OH)2D3 as a posi­
tive control with varying treatments. The timeframe has been set to 7 days, stimulat­
ing the cells every second day. A baseline control for this alkaline phosphatase produc­
tion consisted of cells cultured in the absence of vitamin D3. After the incubation pe­
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riod, cells were harvested in 0.4 M of Tris buffer and sonicated, and the alkaline phos­
phatase activity in the supernatant was measured spectrophotometrically at 405 nm. 
Values obtained were compared with a standard curve using p-nitrophenol as stan­
dard. Data were expressed as micro-moles of alkaline phosphatase activity per milli­
gram of protein. Protein concentration in the supernatants was assessed using the 
BioRad method (BioRad, Mississauga, Ontario, Canada). 
11.5. Calcium measurements 
Calcium measurements have been performed in two different ways, by using 
the Von Kossa method and using a calcium assay kit, commercially available. 
The cells were seeded at 200,000 cells/well (100,000/cm2) in 24 wells plate and 
conditioned for 35 days, every second day. 
The mineralising buffer medium used contains the complete culture medium 
supplemented with 5 mM ^-glycerophosphate, 50|JM L-ascorbate (vitamin C). The 
Dexamethasone was added as a positive control for mineralisation at 10 7M. 
Before analysis, the wells are washed and incubated for 24 hours at room tem­
perature with 0.5ml solution HC10.6N. 
For the Von Kossa method the cells have been washed with 1 ml PBS, fixed 
with 1 ml EtOH 100% and then left for 15 minutes. The EtOH residues were removed 
by washing the wells with distilled water several times. 
In each well we added 3 ml of 5% silver nitrate solution (Sigma) end exposed 
the plate in bright light for 60 minutes. The wells have been washed 5 times with dis­
tilled water to remove the traces of silver nitrate and then left with 3 ml of sodium 
thiosulphate solution (5%) for 2 minutes. After washing again the wells with distilled 
water, they have been finally dehydrated and fixed with EtOH 95% for 2 minutes. 
Pictures of each well were taken using a Nikon camera attached to the micro­
scope and the following settings: 
- blue filter; 
5° 
- intensity: 3; 
- smallest objective (Zeiss 2.5/0.08); 
- camera balance-AUTO 
- camera gain +12dB, FIX; 
- camera detail: on/gamma: 1/D-SUB OUT: RGB. 
The Ca2+ quantification has been also done using an analysis commercial kit -
QuantiChrom™ colorimetric assay - designed to measure calcium directly in biologi­
cal samples without any pretreatment. A phenolsulphonephthalein dye in the kit 
forms a very stable blue colored complex specifically with free calcium. The intensity 
of the colour measured at 612 nm, is directly proportional to the calcium concentra­
tion in the sample (mg/dl or 250 piM Ca2+). 
11.6. Data analysis 
Data were analysed with Mann-Whitney two-tailed non-parametric test using 
Prism 4 software (GraphPad Software, San Diego, CA, USA) and p < 0.05 was consid­
ered significant. Mean ±S.E.M are represented on the graph. The numbers of donors 
(different cell lines) is marked as "N". The statistical significance in the graphs has 
been marked with a sign for the statistical significance of p< 0.05, or "**" for p< 
0.01. The represents the condition they have been compared to. 
111. Results 
In this chapter we present the results of the experimental assays on the human 
osteoblastic cells. We have tried to assess the proliferation, differentiation and matrix 
mineralisation on primary cultures of hOB by treating human osteoblasts in culture 
with different concentrations of PGD2 or the corresponding agonists/antagonist of 
PGD2 receptors. In non-stimulated conditions, the hOB do not produce detectable 
quantities of PGs. 
III.l. Proliferation of the cultured human osteoblastic cells. 
The osteoblast proliferation was determined by incorporation of [^thymid­
ine. The [3HJthymidine is incorporated only into newly forming DNA, thus being an 
indicator of the cell advancement through the osteoblast lineage (Aubin, 1998). It is 
known that mature osteoblasts and osteocytes do not divide, therefore the radio-
labelled thymidine appears in the pre-osteoblasts (Timothy R. Arnett, 1998). 
As described in the Methods chapter, we analysed the incorporation of 
[3H]thymidine (2 pCi/ml) for lines of cells stimulated with different concentrations of 
PGD2. We used the same method for the agonists/antagonists of the PGD2 receptors. 
III. 1.1. Time-course proliferation assay 
The first assay was in fact a time-course assessment of the incorporated radio-
labelled thymidine at different timeframes. 
When the cells have reached the confluence, they have been trypsinized, 
seeded in 24-well plates at 30000 cells/well and allowed to adhere for 24 hours before 
starting the stimulation. The cells have been stimulated with PGD2, BW245C (DP spe­
cific receptor agonist) and DK-PGD2 (CRTH2 specific agonist), respectively. The con­
centrations used were of 1 pM. 
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Fig.18: Effect of the PGD2, BW245C (DP specific receptor agonist) and DK-PGD2 
(CRTH2 specific agonist), all at 10 6 M, on human osteoblast cell proliferation de­
termined by incorporation of [3H]thymidine (2 jjCi/ml) - time course. The control 
(vehicle) considered as the baseline has been removed from graph, but is marked as 
100%. The added PC's represented as percentage of control. The parameter meas­
ured: number of radioactive counts/well. N=3. Mean ±S.E.M. One-way ANOVA. 
Three lines of hOB have been stimulated for different periods of time with 
afore mentioned compounds. No COX inhibitors have been added. The determina­
tions were represented as a percentage compared to the control (Fig. 18). 
Exogenous PGD2 decreased the newly formed DNA at around 75%, compared 
to control. The effect was even more visible for the BW245C and DK-PGD2. The have 
decreased the effect to 30% and 40%, respectively. However, no significant change has 
been detected for the same compound trough different timeframes using the one-way 
ANOVA, hence allowing us to establish the 24h timeframe for proliferation as suit­
able. 
111.1.2. Overall effect of exogenous PGD2 / agonists on proliferation 
To assess the effects of the exogenous PGD-like compounds over the cultured 
hOB, we tested the effects of PGD2, BW245C (DP specific receptor agonist) and DK-
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PGD2 (CRTH2 specific agonist) on the proliferation of the cells in a comparative test 
(Fig. 19). 
The confluent cells have been detached with trypsin, seeded in 24-well plates 
at 30000 cells/well and allowed to adhere for 24 hours before starting the stimulation. 
Subsequently, the cells have been stimulated with PGD2 (1 (iM), BW245C (1 pM) and 
DK-PGD2 (1 (JM) in presence of Diclofenac, a nonspecific COX inhibitor (1 jaM), and 
Naproxen (10 (iM) alone for 24 hours. The "Normal" condition represents the non-
stimulated wells, containing the solvent vehicles. The Naproxen has been added for all 
conditions to insure that the endogenous production of prostaglandins is being 
seized. 
PGD2, BW245C and DK-PGD2 
100-
Fig. 19: Effect of the PGD2, BW245C (DP specific receptor agonist) and DK-PGD2 
(CRTH2 specific agonist) on human osteoblast cell proliferation determined by 
incorporation of [3H]thymidine (2 [iCi/ml) - in the presence of Naproxen. The 
Naproxen condition is considered as the baseline and marked as 100%. The 
added PG's represented as percentage of Naproxen. The parameter measured: 
number of radioactive counts/well N=5. Mean ±S.E.M. Two-tailed non-
parametric test. **p< 0.01. 
On a 24 stimulation in the presence on nonspecific COX inhibitors, we can 
observe a decrease of the measured parameter for proliferation for PGD2 and DK-
PGD2 to 65% when compared to Naproxen (N=5. Mean ±S.E.M. Two-tailed non-
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parametric test. ** p< 0.01). However, no effect is seen for the BW245C condition, 
although it decreased the measured effect to 90%. 
111.1.2. The effect of different concentrations of exogenous PGD2 on 
hOB proliferation 
In the next series of experiments we tested the effect of PGD2 at different con­
centrations on 6 different lines of hOB. We used two different nonspecific COX in­
hibitors to block the endogenous PG production: Naproxen was used at a concentra­
tion of 10 |iM and Diclofenac at 1 |iM, the latter having a negative impact on hOB pro­
liferation at higher concentrations (Matziolis et al., 2002; Kaspar et al., 2005). 
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Fig. 20: The effect of different concentrations of exogenous PGD2 on human 
osteoblast cell proliferation determined by incorporation of [3H]thymidine (2 
[iCi/ml). The control condition (Vehicle) is considered as the baseline and 
marked as 100%. The added PG's and NSA1D represented as a percentage of 
control. The parameter measured: number of radioactive counts/well. N=6. 
Mean ±S.E.M. Two-tailed non-parametric test. ** p< 0.01. 
In the first test (Fig. 20), we have added the PGD2 at different concentrations, 
varying from 10"10 M to 10"6 M. We have not inhibited the local production of endoge­
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nous prostaglandins with any of the mentioned COX blockers. We observed a signifi­
cant change between the control and the conditioned wells. The added PGD2 de­
creased significantly the newly formed DNA (N=6. Mean ±S.E.M. Two-tailed non-
parametric test. ** p< 0.01). The PGD2at 1010 decreased the effect at 55%, PGD2at 10 8 
decreased the effect at 45% and PGD2 at 10"6 decreased the effect at 35% compared to 
Control (vehicles). 
In the second test (Fig. 21), we added Naproxen in all conditioned wells (10 ^M) 
except for the control. The same protocol was used for the stimulation. The parame­
ter measured was the number of radioactive counts/well after the 24 hour stimulation 
in presence of [3H]thymidine (2 pCi/ml). The PGD2 was used at different concentra­
tions, varying from 1040 M to 106 M. 
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Fig. 21: The effect of different concentrations of exogenous PGD2 on human 
osteoblast cell proliferation determined by incorporation of[3H]thymidine (2 
\lCi/ml) in the presence of Naproxen. The control condition (Vehicle) is consid­
ered as the baseline and marked as 100%. The added PG's and NSA1D repre­
sented as a percentage of control. The parameter measured: number of radio­
active counts/well. Naproxen added to every condition, except control. N=6. 
Mean ±S.E.M. Two-tailed non-parametric test. *p< 0.05. 
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Both the Naproxen and the PGD2 at 10"10 M decreased the effect at 90% of 
Control (vehicles). The PGD2 at 10 9 M and PGD2 at 10"8 M decreased the effect at 
around 80% of Control. The PGD2at 10"7 decreased the effect at 60% and the PGD2at 
10'6 at 40%. By comparing the Naproxen conditioned wells to PGD2 stimulated wells, 
we observed a significant inhibiting effect on the hOB proliferation, but only for 
PGD2 at 10"7M and 10~6M. Although not statistically significant, the PGD2 at 10_9M 
and 10 8M could have also an effect suggesting a dose-response effect (N=6. Mean 
±S.E.M. Two-tailed non-parametric test. * p< 0.05). 
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Fig. 22: The effect of different concentrations of exogenous PGD2 on human 
osteoblast cell proliferation determined by incorporation of [3H]thymidine (2 
HCi/ml) in the presence of Diclofenac. The control condition (Vehicle) is con­
sidered as the baseline and marked as 100%. The added PG's and NSA1D repre­
sented as a percentage of control. The parameter measured: number of radio­
active counts/well. Diclofenac added to every condition, except control. N=6. 
Mean ±S.E.M. Two-tailed non-parametric test. **p< 0.01. 
In the third test (Fig. 22) we inhibited the COX enzyme with Diclofenac at 1 
[iM added in every conditioned well, except the control. The PGD2 was used at differ­
ent concentrations, varying from 10*10 M to 10"6 M. 
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The Diclofenac alone decreased the measured effect at 95% of the Control (ve­
hicles). The PGD2at 10"10and the PGD2at 1010 both yielded the same efect, decreasing 
the proliferation at around 73% of the Control. We saw a significant decrease of the 
synthesised DNA only for a concentration of 10 6M PGD2, although the trend might 
suggest a dose-response effect (N=6. Mean ±S.E.M. Two-tailed non-parametric test. ** 
p< 0.01). 
UI.1.3. The effect of different concentrations of BW245C (DP spe­
cific receptor agonist) on hOB proliferation 
We performed a series of experiments using the BW245C (DP specific receptor 
agonist). The used protocol was the same as the one used for the PGD2 series. 
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Fig. 23: Effect of the BW245C on human osteoblast cell proliferation deter­
mined by incorporation of [3H]thymidine (2 [JCi/ml) at different concentra­
tions. The control condition (Vehicle) is considered as the baseline and 
marked as 100%. The added BW245C is represented as a percentage of con­
trol. The parameter measured: number of radioactive counts/well. N=5. Mean 
±S.E.M. Two-tailed non-parametric test. 
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In the first assay (Fig. 23), we have compared the stimulated conditions to the 
control. No NSAlDs have been used. We have used increasing concentrations of 
BW245C from 10"10M up to HHM. 
We observed an increase of the positive effect over the proliferation (up to 
25%) with the increasing concentrations of BW245C up to 10_8M. For the wells condi­
tioned with BW245C at 10"7M, we observed a drop of 85% compared to the Control, 
but we think that the effect cannot be taken into consideration because of the wide 
errors. The last sample (BW245C at 10 6M) seem to be continuing the trend. No statis­
tically significant effect could be assessed (N=5. Mean ±S.E.M. Two-tailed non-
parametric test). 
In the second test (Fig. 24), by using the same protocol as described, we added 
Naproxen to every conditioned well, simply to remove any endogenous PG's through 
the nonspecific inhibition of COX enzyme. 
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Fig. 24: Effect of the BW245C on human osteoblast cell proliferation deter­
mined by incorporation of [3H]thymidine (2 \iCi/ml) at different concentra­
tions in presence of Naproxen. The control condition (Vehicle) is considered as 
the baseline and marked as 100%. The added BW245C and the Naproxen are 
represented as a percentage of control. The parameter measured: number of 
radioactive counts/well. N=5. Mean ±S.E.M. Two-tailed non-parametric test. 
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The stimulated conditions have been compared to the Naproxen, this one be­
ing present in all the wells. Naproxen, BW245C at 10"8 and BW245C at 10 6 M gave an 
increase of the measured effect of 5-8% when compared to Control. BW245C at 1010 
and BW245C at 10 9 responses were comparable to the Control, while The BW245C at 
10_7M lowered the effect at around 85%. 
Compared to Naproxen, there is no statistically significant correlation to 
BW245C at any concentration of BW245C (N=5. Mean iS.E.M. Two-tailed non-
parametric test). 
The third test was similar (Fig. 25), but we replaced the Naproxen with Diclo­
fenac (nonspecific COX inhibitor). The Diclofenac has been added to all wells, except 
the control. Again, the Diclofenac was used at a concentration of 1 [jM to avoid the 
deleterious effects. Diclofenac had a positive effect on proliferation of around 10%, 
Fig. 25: Effect of the BW245C on human osteoblast cell proliferation deter­
mined by incorporation of [3H]thymidine (2 \iCi/ml) at different concentra­
tions in presence of Diclofenac. The control condition (Vehicle) is considered 
as the baseline and marked as 100%. The added BW245C and the Diclofenac 
are represented as a percentage of control. The parameter measured: number 
of radioactive counts/well. N=5. Mean ±S.E.M. Two-tailed non-parametric 
test. 
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when compared to Control (vehicles). BW245C at 1010 M response was comparable to 
the Control. BW245C at 10'9 response was 5% higher than the Control, while BW245C 
at 10"8 decreased the effect at around 80%. The BW245C at 107 M increased the effect 
at over 10% compared to the Control and the BW245C at 10 6at around 9%. 
We have not seen an important effect or a significant variance comparing the 
Diclofenac to the stimulated conditions (N=5. Mean ±S.E.M. Two-tailed non-
parametric test). 
I1I.1.4. The effect of different concentrations of DK-PGD2 (CRTH2 
specific agonist) on hOB proliferation 
We performed a series of three tests similar to the former ones. The protocol 
used is the same as the one described. The parameter measured was the number of 
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Fig. 26: Effect of different concentrations ofDK-PGD2 on human osteoblast 
cell proliferation determined by incorporation of[3H]thymidine (2 \iCi/ml). 
The control condition (Vehicle) is considered as the baseline and marked as 
100%. The added DK-PGD2 is represented as a percentage of control. The pa­
rameter measured: number of radioactive counts/well. N-5. Mean ±S.E.M. 
Two-tailed non-parametric test. 
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radioactive counts/well after the 24 hour stimulation in presence of [3H]thymidine (2 
pCi/ml). In the first assay (Fig. 26) we have compared the stimulated conditions to the 
control (vehicles) using the DK-PGD2 in a range of concentrations from 1010 M to 10 6 
M. No NSAlDs have been used. While the DK-PGD2 at 10"10 M had an effect compara­
ble to the Control (vehicles), the DK-PGD2 at lO9 M decreased the effect at 75% of 
Control, and the DK-PGD2 at 10 s M lowered that effect at 65%. Surprisingly, DK-PGD2 
at 10"7 M and DK-PGD2 at 10 6 M restored the effect at 95% and 90%, respectively. 
One can observe a tendency of proliferation decrease towards the higher con­
centrations of DK-PGD2, but this stops suddenly at 10"8M - not a statistically relevant 
value (N=5. Mean ±S.E.M. Two-tailed non-parametric test). 
The second test (Fig. 27) of this series is performed using the Naproxen to 
block the endogenous PG's production (10 [iM). We have compared the stimulated 
Fig. 27: Effect of different concentrations ofDK-PGD2 on human osteoblast 
cell proliferation determined by incorporation of [3H]thymidine (2 \lCi/ml) in 
presence of Naproxen. The control condition (Vehicle) is considered as the 
baseline and marked as 100%. The added DK-PGD2 and the Naproxen are 
represented as a percentage of control. The parameter measured: number of 
radioactive counts/well. N=5. Mean ±S.E.M. Two-tailed non-parametric test. 
* * p< 0.01. 
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conditions to Naproxen (present for every condition) using the DK-PGD2 in a range of 
concentrations from 10"10 M to 10"6 M. The Naproxen increased the effect with around 
7% when compared to the Control (vehicles). DK-PGD2 at 1010 M and at 10 9 M de­
creased the proliferation to 70% and 55%, respectively. DK-PGD2 at 10 8 M, at 10'9 M 
and DK-PGD2 at 10~6 yielded effects going over 100%. 
We observed a dose-dependent effect which stops suddenly when the DK-
PGD2 reaches a concentration of 10"9M, the only significant value. Surprisingly, for the 
following conditions the measured effect level is similar to that of Naproxen (N=5. 
Mean ±S.E.M. Two-tailed non-parametric test). 
The third assay (Fig. 28) using the DK-PGD2 concentrations ranging from 10" 
10M to 10'6 M has been performed using Diclofenac as an inhibitor of the local PG's 
production - added to all conditioned wells. Diclofenac alone had a positive effect on 
Fig. 28: Effect of different concentrations ofDK-PCD2 on human osteoblast 
cell proliferation determined by incorporation of [3H]thymidine (2 [lCi/ml) in 
presence of Diclofenac. The control condition (Vehicle) is considered as the 
baseline and marked as 100%. The added DK-PGD2 and the Diclofenac are 
represented as a percentage of control The parameter measured: number of 
radioactive counts/well. N=5. Mean ±S.E.M. Two-tailed non-parametric test. 
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the proliferation of 110% when compared to Control (vehicles). DK-PGD2 at 1010 M 
and at 10"9 M had an effect comparable to Control. DK-PGD2 at 10'8 M lowered the ef­
fect to 85%. DK-PGD2 at 10 7 M and at 10 6 M continued this trend, going to 70% and 
60%, respectively. 
No significant effect is seen, however the proliferation seems diminished com­
pared to control, suggesting a dose-response effect for the increasing concentrations 
of DK-PGD2 compared to the Diclofenac (N=5. Mean ±S.E.M. Two-tailed non-
parametric test). 
II1.2. Differentiation of the cultured human osteoblastic cells 
Skeletal alkaline phosphatase (ALP) is an enzyme localised in the membrane of 
osteoblasts which is released into the circulation by an unclear mechanism. The en­
zyme is considered as a marker for the mature osteoblast and we must mention that 
along with its secretion, the mineralisation takes place. (Marc C. Hochberg, 2003) 
The method used has been described in the "Methods" chapter. Briefly, the 
confluent cells have been detached with trypsin, seeded in 24-well plates at 120,000 
cells/well and allowed to adhere for 24 hours before starting the stimulation. The 
positive control is the Vitamin D used at 10 9M. 
Alkaline phosphatase has been quantised as ALK/proteins [fjmol/mg] for each 
conditioned well. The timeframe has beed set to 7 day, stimulating the cells every sec­
ond day (Maciel et al., 1997; Morisset et al., 1998; da Rocha & de Brum-Fernandes, 
2002). 
111.2.1. Effect of different concentrations of exogenous PGD2 on the 
differentiation of human osteoblasts 
In the first experiment (Fig. 29) we have used the PGD2 at three different con­
centrations (1010M, 10"8M and 106M) in order to measure the effect on the two recep­
tors, DP and CRTH2. The endogenous production of PG's has not been blocked with 
NSA1D. Vitamin D stands as positive control. 
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The vitamin D alone yielded a 400% increase of differentiation compared to 
the Normal, non-stimulated condition. The PGD2 at three different concentrations 
(10~10M, 10 8M and 10"6M) had almost the same effect as the Normal condition, with 
just a few percents below the marked 100% line. 
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Fig. 29: Effect of different concentrations of exogenous PGD2 on the differen­
tiation of human osteoblasts. The control condition (Normal or Vehicle) is 
considered as the baseline and marked as 100%. The Vitamin D is represented 
as positive control. The parameter measured: pmol AlkPJmg protein. N=6. 
Mean ±S.E.M. Two-tailed non-parametric test. 
No statistical significant variation has been observed (N=6. Mean ±S.E.M. 
Two-tailed non-parametric test). 
The second assay (Fig. 30) reproduces the previous one, but using the 
Naproxen (10 5M) as a COX inhibitor in all conditioned wells and the PGD2 at three 
different concentrations (1010M, 10'8M and 10_6M). Vitamin D stands as positive con­
trol. 
For this test, the Naproxen condition has been considered as 100%, this COX 
inhibitor being added to all stimulated wells. When comparing the Normal condition 
with the Naproxen, we can say that the latter impaired the differentiation. 
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Fig. 30: Effect of different concentrations of exogenous PGD2 on the differen­
tiation of human osteoblast in presence of Naproxen. The Naproxen is con­
sidered as the baseline and marked as 100%. The Vitamin D is represented as 
positive control. The parameter measured: pmol AlkP/mg protein. Normal 
stands for Vehicle. N=6. Mean ±S.E.M. Two-tailed non-parametric test. 
Vitamin D had a positive effect of 540%. The PGD2 at 1010M yielded a positive 
effect of roughly 110% when compared to Naproxen. For the two other concentrations 
used - 10 8M and 10'6M - we consider that the effect is similar with the one given by 
Naproxen. 
No correlation could be established between the dose of the added PG's and 
the production of AlkP when comparing the conditioned wells to the Naproxen which 
was present in all conditions (N=6. Mean ±S.E.M. Two-tailed non-parametric test). 
The third assay is similar (Fig. 31), but we used Diclofenac as an endogenous 
PG inhibitor at 10 6M for the conditioned wells and the PGD2 at three different con­
centrations (1010M, 10"8M and 10'6M). Vitamin D stands as positive control and had a 
positive effect of around 250% compared to the Diclofenac standard. Diclofenac alone 
had a positive impact on differentiation, compared to the Normal (vehicles) condition. 
66 
PGD2 + Diclofenac 
350 
300-
g 250-CO 
£ 200-
o 
.2 160H Q 
S? 100+ 
50-
0-
4* <?N <jr <$r ^ < *^V j^ xV 
Fig. 31: Effect of different concentrations of exogenous PGD2 on the differen­
tiation of human osteoblast in presence of Diclofenac. The Diclofenac is con­
sidered as the baseline and marked as 100%. The Vitamin D is represented as 
positive control. The parameter measured: pmolAlkP/mg protein. Normal 
stands for Vehicle. N=6. Mean ±S.E.M. Two-tailed non-parametric test. * p< 
0.05. 
We did not see a significant modification for the production of AlkP, except for 
the PGD2 at 10 6M compared to the Diclofenac (N=6. Mean ±S.E.M. Two-tailed non-
parametric test. * p< 0.05). The two other conditions - PGD2 at 10"10M and 10~8M - had 
a response comparable to the one given by Diclofenac. 
111.2.2. Effect of different concentrations of exogenous PGD2 on the 
differentiation of human osteoblasts in presence of DP-receptor and 
CRTH2-receptor antagonists 
In the next test (Fig. 32) we used a DP antagonist - BWA868C and a CRTH2 
antagonist - CAY10471, both at 10"6 M (Ulven & Kostenis, 2005; Royer et al., 2007). 
The PGD2 has been used at 10"10M, 10"8M, and 10 6M, in competition with each one of 
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the afore mentioned antagonists. No COX blockers have been added; the vitamin D 
stands as a positive control. The vitamin D yielded a positive effect of 200%. 
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Fig. 32: Effect of different concentrations of exogenous PGD2 on the differentia­
tion of human osteoblasts in presence of DP and CRTH2 antagonists. The 
Normal (vehicles) is considered as the baseline and marked as 100%. The added 
PGD2 and the antagonists (10'6M) are represented as a percentage of control. 
The parameter measured: pimol AlkP/mg protein. N=5. Notation: BWA-DP an­
tagonist; CAY=CRTH2 antagonist. Normal stands for Vehicle. Mean ±S.E.M. 
Two-tailed non-parametric test. * p< 0.05. 
Except for the CAY10471 (CRTH2 antagonist)/PGD2 10"6M condition no sig­
nificant effect is observed compared to the control. The CAY10471/PGD2 10 6M is at 
95% for the measured effect, this could suggest a possible decreasing effect with con­
centration (N=5. Mean ±S.E.M. Two-tailed non-parametric test. * p< 0.05). 
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111.2.3. Effect of different concentrations of exogenous PGD2 on the 
differentiation of human osteoblasts in presence of T0070907, a selec­
tive antagonist of the human PPARy nuclear receptor 
The next assay (Fig. 33) was meant to provide some information over the ac­
tion of the PGD2 on the PPARy receptor (Dussault & Forman, 2000b; Khan & Abu-
Amer, 2003; Bell-Parikh et al., 2003; Lecka-Czernik & Suva, 2006). 
PGD2 + PPAR antagonist 
400-
E 
| 300- -r-
Fig. 33: Effect of different concentrations of exogenous PGD2 on the differen­
tiation of human osteoblasts in presence ofT0070907, a selective antagonist 
of the human PPARy nuclear receptor. The Normal (Vehicle) is considered as 
the baseline and marked as 100%. The added PGD2 and the PPARy antago­
nist (10'6M) are represented as a percentage of control (PPAR and the PGD2 
at molar concentration). The parameter measured: fimol AlkP/mg protein. 
N=4. Notation: AntPPAR = PPAR antagonist. Normal stands for Vehicle. 
Mean ±S.E.M. Two-tailed non-parametric test. 
69 
We have used the same protocol described for the determination of AlkP. The 
PPARy receptor antagonist chosen was T0070907, a highly selective compound active 
on human PPARy receptor (Lee et al., 2002) at 10 6M. No NSAlD's have been used. 
The PGD2 has been used at 10~10M, 10~8M, and 10~6M, alone and in conjunction with 
T0070907. The vitamin D has been added as a positive control and yielded a positive 
effect of over 200% compared to the Normal (vehicle condition). The PGD2 at 1010M/ 
PPAR Ant and PGD2 at 10 8M/PPAR Ant decreased the measured effect to around 60%, 
while PGD2 at 10 6M/PPAR Ant went to 40% when compared to Normal condition. 
The combination PGD2/PPARY antagonist decreased the alkaline phosphatase 
production, but without statistical significance (N=4. Mean ±S.E.M. Two-tailed non-
parametric test). No COX blockers have been added; the vitamin D stands as a positive 
control. 
111.2.4. Effect of different concentrations of exogenous PGD2 on the 
differentiation of human osteoblasts in the presence of Vitamin D 
In order to assess the influence of vitamin D on the AlkP production, we have 
performed a series of tests by adding vitamin D (10~9 M) in every conditioned well. 
The first assay (Fig. 34) have used the PGD2 at three different concentrations: 
10-i°M, 10 8M and 10~6M. No COX inhibitor has been added. 
Vitamin D had more than a double the effect of the non-stimulated condition 
(Normal) and being present in all conditions has been chosen as reference. The PGD2 
at 1010M had almost the same effect as the vitamin D condition. PGD2 at 10'8M de­
creased the measured effect to 80% and PGD2 at 10 6M decreased the effect at 65% 
when compared to the vitamin D reference. 
We observed a dose-response trend line comparing the VitD control with the 
increasing concentrations of PGD2, although not statistically proven for the entire se­
ries (N=5. Mean ±S.E.M. Two-tailed non-parametric test. * p< 0.05; ** p< 0.01). 
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Fig. 34: Effect of different concentrations of exogenous PGD2 on the differen­
tiation of human osteoblasts in the presence ofVitD. The vitamin D is con­
sidered as the baseline and marked as 100%. The added PGD2 are represented 
as a percentage of control. The parameter measured: /umol AlkP/mg protein. 
Normal stands for Vehicle. N=5. Mean ±S.E.M. Two-tailed non-parametric 
test. * p< 0.05; ** p< 0.01. 
In the second experiment of these series (Fig. 35), we used Naproxen (10_5M) to 
block the local PG production and PGD2 at three different concentrations: 1010M, 10" 
8M and 10_6M. Vitamin D is present (10 "9 M) in every conditioned well. 
Vitamin D had more than a double the effect of the non-stimulated condition 
(Normal) and being present in all conditions has been chosen as reference. Naproxen 
yielded an increased effect of 110% compared to the vitamin D reference. Naproxen is 
present in all the samples containing PGD2. The PGD2 at 104°M/Naproxen and PGD2 
at 10"8M/Naproxen had an 85% effect when compared to vitamin D standard. The 
PGD2 at 10 6M/Naproxen had the same effect as the vitamin D alone. 
The PGD2 conditions did not show a dose-response trend-line compared to 
the VitD control (N=5. Mean ±S.E.M. Two-tailed non-parametric test). 
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Fig. 35: Effect of different concentrations of exogenous PGD2 on the differen­
tiation of human osteoblasts in the presence ofVitD and Naproxen. The vi­
tamin D is considered as the baseline and marked as 100%. The added PGD2 
and the Naproxen (10~SM) are represented as a percentage of control. The 
parameter measured: fimolAlkP/mg protein. Normal stands for Vehicle. N-5. 
Mean ±S.E.M. Two-tailed non-parametric test. 
In the third experiment of these series (Fig. 36), we used Diclofenac (10~6M) to 
block the local PG production and PGD2 at three different concentrations: 10-10M, 10-
8M and 10 6M. Vitamin D is present (10 '9 M) in every conditioned well. The Diclofenac 
is present in all the samples containing PGD2. 
Vitamin D had more than a double the effect of the non-stimulated condition 
(Normal) and being present in all conditions has been chosen as reference. PGD2 at 
10-i°M, 10"8M and 10"6M yielded decreased effects when compared to vitamin D (stan­
dard) of 90%, 80% and 70%, in this order. 
No significant effect is seen for the any of the conditions, although the de­
crease of the measured parameter with the increasing concentrations of PGD2 could 
suggest a dose-response (N=5. Mean ±S.E.M. Two-tailed non-parametric test). 
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Fig. 36: Effect of different concentrations of exogenous PGD2 on the differen­
tiation of human osteoblasts in the presence ofVitD and Diclofenac. The vi­
tamin D is considered as the baseline and marked as 100%. The added PGD2 
and the Diclofenac (10~6M) are represented as a percentage of control The 
parameter measured: /umol AlkP/mg protein. Normal stands for Vehicle. N=5. 
Mean ±S.E.M. Two-tailed non-parametric test. 
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111.3. Matrix mineralisation (calcification) from the cul­
tured human osteoblastic cells 
The mature osteoblast shows all the functions necessary in bone synthesis. 
The mineralisations is the following step after the organic matrix has been created. 
The active osteoblasts surround themselves by this matrix and this is the point where 
the crystals of hydroxyapatite begin to form. 
To measure the hOB capacity of generating mineral bone tissue, we deter­
mined the secreted Ca2+ in different conditions after a period of 35 days. Briefly, cells 
are seeded at the ratio of 200,000 cells/well in 24 well plates and cultured in media 
containing 10 mM 3-glycerophosphate and 50 (Jg/ml ascorbic acid. Dexamethasone 
has been used as a positive control.(Cheng et al., 1996; Mikami et al., 2007). The cells 
are washed and incubated 24 h at room temperature with 0.5 ml 0.6 N HC1. 
The Ca2+ quantification has been also done using a colorimetric assay designed 
to measure calcium directly in biological samples without any pretreatment. A phe-
nolsulphonephthalein dye in the kit forms a very stable blue colored complex specifi­
cally with free calcium. The intensity of the color measured at 612 nm, is directly pro­
portional to the calcium concentration in the sample (mg/dl or 250 |JM Ca2+). 
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II1.3.1. Effect of different concentrations of exogenous PGD2 on the 
calcification of human osteoblasts. Silver staining von Kossa method. 
The cells have been stimulated with different concentrations of PGD2 (1010M 
to 10'6M) in presence of Naproxen. After 35 days in stimulated conditions, an adapted 
von Kossa method has been used (Fig. 37). 
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Fig. 37: Effect of different concentrations ofPGD2 on human osteoblast cell calcification in presence 
of Naproxen. Dexamethasone used as positive control at 10~7M. Vitamin C added at in all samples 
except Control (10~4M). Naproxen added to all PG samples at 10'5M. p-glycerophosphate added in 
all wells except Control. N=7. Normal stands for Vehicle. 
A certain effect for the wells containing PGD2 is sometimes noticeable. How­
ever, there is no dose-response relationship as we increased PGD2 concentration fur­
ther away. A slightly positive effect on calcification can be seen for the Naproxen 
conditions for a few cell lines. 
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111.3.2. Effect of exogenous PGD2 in presence of DP-receptor and 
CRTH2-receptor antagonists on the calcification of human osteo­
blasts. Silver staining von Kossa method. 
In this assay we used the DP antagonist - BWA868C (1010 M to 10"6 M) and the 
CRTH2 antagonist - CAY10471 (10"10 M to 10"6 M) in competition with PGD2 used at 
10 9M. The only noticeable effect for calcification was seen for BWA868C at 10 6 M 
and the CAY10471 at 10 6 M (Fig. 38). 
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Fig. 38: Effect ofDP/CRTH2 receptor antagonists (in the presence ofPGD210-9M) on human os­
teoblast calcification in presence of Naproxen. Dexamethasone used as positive control at 10'7M. 
Vitamin C added at in all samples except Control (10~4M). Naproxen added to all agonist samples 
at 10~SM. 3-glycerophosphate added in all wells except Control. N=3. Notation: BWA/CAY = 
BWA868C/CAY10471. Normal stands for Vehicle 
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111.3.3. Effect of different concentrations of exogenous PGD2 on the 
calcification of human osteoblasts. QuantiChrom™ colorimetric assay. 
Considering the von Kossa method less accurate, this time the Ca2+ quantifica­
tion has been done using an analysis commercial kit. 
For this test (Fig. 39) we used three different concentrations of PGD2: 1010M, 
10_8M and 10~6M. The Naproxen is present in all conditioned wells and has been cho­
sen as reference. Dexamethasone was used as positive control at 10"7M. Vitamin C was 
added in all samples (1CHM). 
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Fig. 39: Effect of different concentrations of PGD2 on human osteoblast calcification in presence of 
Naproxen - colorimetric. Dexamethasone used as positive control at 10'7M. Vitamin C added at in 
all samples (10~4M). Naproxen added to all PG samples (at 10~SM) is represented as 100%. {$-
glycerophosphate added in all wells. Parameter measured Ca2+ concentration (mg/dl). N=6. Mean 
±S.E.M. Two-tailed non-parametric test. 
The results obtained using this analysis are more accurate. The Dexametha­
sone alone had a 2000 times the effect of the Naproxen standard. The PGD2 at 1010M 
showed a decreased effect of 80%. The PGD2 at 10~8M and PGD2 at 10"6M showed an 
increased effect of 130% and 150%, respectively. 
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Although one could suspect a dose-response effect when comparing the PGD2 
samples against Naproxen, no statistically relevant response is seen (N=6. Mean 
±S.E.M. Two-tailed non-parametric test). 
111.3.4. Effect of exogenous PGD2 in presence of DP-receptor and 
CRTH2-receptor antagonists on the calcification of human osteo­
blasts. QuantiChrom™ colorimetric assay. 
In Fig. 40 we show the results of a competition test with PGD2 at 10 9M and 
two antagonists, for the DP and CRTH2 receptor, respectively. The antagonists have 
been used at different concentrations: 10"10M, 10"8M and 10_6M. Dexamethasone was 
used as positive control at 10_7M. Vitamin C was added in all samples (10"4M). 
PGD2 + DP/CRTH2 Antagonists 
Fig. 40: Effect ofDP/CRTH2 antagonists on human osteoblast calcification in presence ofPGD2 (10 
9M). Dexamethasone used as positive control at 10~7M. Vitamin C added at in all samples (104M). 
Naproxen added to all PG samples at 10-SM is represented as 100%. 0-glycerophosphate added in 
all wells. Parameter measured Ca2+ concentration (mg/dl). N=5. Notation: BWA/CAY = BWA868C/ 
CAY10471. Mean ±S.E.M. Two-tailed non-parametric test. 
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Dexamethasone had a positive effect of 700% roughly when compared to the 
Naproxen standard. The BWA868C at 1010M/Naproxen yielded the same effect as 
Naproxen alone. The BWA868C at 10 8M/Naproxen decreased the effect to around 
80%, and the BWA868C at 10 6M/Naproxen decreased the effect at around 85% com­
pared to the Naproxen reference. 
The CAY10471 at 1010M/Naproxen and the CAY10471 at 10 6M/Naproxen had 
almost the same effect as Naproxen alone, while CAY10471 at 10 8M/Naproxen 
showed a decreased effect of around 80%. 
There is no significant change between the control (Naproxen) and the stimu­
lated conditions for either of the two antagonists used (N=5. Mean ±S.E.M. Two-tailed 
non-parametric test). 
111,3.5. Effect of different concentrations of exogenous PGD2 on the 
calcium production of human osteoblasts in presence of T0070907, a 
selective antagonist of the human PPARy nuclear receptor. Quanti-
Chrom™ colorimetric assay. 
The PPARy receptor antagonist used was T0070907, a highly specific antago­
nist of the human PPARy receptor at a concentration of 10 6M with PGD2 at 1010M, 
10 8M, and 10 6M. Naproxen at 10 5M has been added in all conditioned wells (Fig. 41). 
Dexamethasone used as positive control at 10 7M. Vitamin C added at in all 
samples (10 4M). 
Dexamethasone, when compared to the Naproxen standard, yielded a 200% 
effect. 
The PGD2 at 1010M/T0070907 condition showed only a slight increase in the 
measured effect when compared to Naproxen standard. The PGD2at 10 8M/T0070907 
lowered the measured effect to about 50%, while PGD2at 10 6M/T0070907 decreased 
it even more, to around 30%. 
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Fig. 41: Effect ofPGD2 in conjunction with T0070907, PPARy antagonist on human os­
teoblast calcification . Dexamethasone used as positive control at 1Q7M. Vitamin C added 
at in all samples{10-4M). Naproxen added to all samples (except Dexa) at 10~5M is repre­
sented as 100%. glycerophosphate added in all wells. Parameter measured Ca2+ concen­
tration (mg/dl). N=4. Notation: AntPP= PPAR antagonist. Mean ±S.E.M. Two-tailed 
non-parametric test. * p< 0.05. 
We observe significant changes for the PGD2 at 10"8M. The treatment seems to 
diminish the calcification, even if the last value AntPP/[PGD2]"6 is not accounted as 
significant (N=4. Mean ±S.E.M. Two-tailed non-parametric test. * p< 0.05). 
IV. Discussion 
Prostaglandins (PGs) are active biologic substances that are involved in a wide 
range of physiologic processes; when their production is out of balance, they are fac­
tors in the pathogenesis of illness. Modulation of PGs by inhibition or stimulation is 
promising for the management of various conditions. 
Prostaglandin synthesis is up-regulated in virtually all forms of inflammation 
including RA. They are produced on demand and are not stored in cells, acting locally. 
The key regulatory step in the production of prostaglandins is the conversion of 
membrane phospholipids to arachidonic acid by the phospholipase A2 (PLA2) family 
of enzymes in response to a variety of stimuli, including pro-inflammatory cytokines, 
lipopolysaccharide, oxidised low-density lipoproteins, and small peptide growth fac­
tors. 
Red meat and certain vegetable oils (corn, sunflower, and safflower) contain 
omega 6 fatty acids, which are transformed into arachidonic acid, the precursor for 
prostaglandins and leukotrienes. Reducing the amount of omega 6 while substituting 
omega 3 oils may help reduce pain and inflammation (Maggio et al., 2009). Omega 3 
fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), fatty ac­
ids that compete with omega 6 fatty acids to form arachidonic acid. In fact, diets high 
in omega 3 fatty acids appear to have a protective effect against rheumatoid arthritis 
onset (Watkins et al., 2003). 
The biologic effects of prostaglandins are numerous. Their role in regulating 
inflammatory responses includes the induction of fever, pain, swelling, and the regu­
lation of leukocyte function. Fever is induced, in part, by local production of PGE2 in 
the brain, through interaction with neurones in the hypothalamus. (Ushikubi et al., 
1998) Prostaglandins do not directly stimulate pain responses, but they contribute to 
pain responses by inducing a state of hyperalgesia. PGE2 and PGI2 cause sensitisation 
of peripheral nerve terminals and modulate pain processing at a central level in the 
spinal cord (Wise, 2006; Burian & Geisslinger, 2005) 
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In addition to the classical prostanoid receptors, new evidence is emerging that 
suggests nuclear receptors for eicosanoids (Negishi & Katoh, 2002). The candidate re­
ceptors identified to date are classified as peroxisome proliferator-activated receptors 
(PPARs) (Giaginis et al., 2007). These nuclear receptors are transcription factors that 
regulate gene expression of enzymes associated with lipid homeostasis. PPARs com­
plex with the nuclear receptor for 9-cis-retinoic acid (RXR) and bind a specific DNA 
motif termed the PPAR-response element (PPRE). Several eicosanoids, including PGJ2 
and LTB4, bind to PPARs and affect transcription. PPREs are present in genes involved 
in the oxidation pathway for metabolism of fatty acids. At least one potentially impor­
tant mechanism underlying PPAR-mediated eicosanoid action is auto-regulation of 
eicosanoid levels through increased synthesis of enzyme-mediating degradation. In 
addition, PPAR agonists, including PGJ2, suppress cytokine production (Xu and Drew, 
2007). 
Non-steroidal anti-inflammatory drugs have been shown to delay fracture 
healing in both clinical series (Giannoudis et al., 2000) and animal models (Altman et 
al., 1995). The mechanism of action is thought to be related to inhibition of prosta­
glandins resulting in delayed ossification by diminishing regional blood flow or hin­
dering primitive osteoblasts. More recently, selective COX-2 non-steroidal anti­
inflammatory drugs have been shown to impair fracture healing (Seidenberg & An, 
2004; Vuolteenaho et al., 2008). 
IV.L. PGD2 
PGD2 is implicated in the control of osteoblast function and bone anabolism. 
In human primary osteoblasts, PGD2 activates the Gs-coupled PGD2 receptor (DP) 
and decreases osteoprotegerin production (Gallant et al., 2005). In the same cells, 
PGD2 decreases RANKL production upon binding to another PGD2 receptor, che-
moattractant receptor-homologous molecule expressed on TH2 cells (CRTH2), which 
couples to Gi/o. Thus, PGD2 appears to have both bone-resorptive and -forming ac­
tivities through two different receptors DP and CRTH2. The latter activity may be re­
sponsible for the anabolic effects of PGD2 on bone in vivo. 
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Two inflammatory cytokines (TNF-a and 1L-1) and three regulators of bone 
formation (PTH, VEGF, and insulin-like growth factor-1) strongly stimulate the pro­
duction of PGD2 in human primary osteoblasts. Mechanical loading by strain applica­
tion increases the mRNA expression of PGD synthase and PPARy-1 in MC3T3-E1 
cells(Siddhivarn et al., 2006). The mechanical loading increases the production of 
PGD2, and its metabolite A12 PGJ2, the natural ligand for PPARy-1 (Siddhivarn et al., 
2007). In addition, stretching of osteoblasts induces bone nodule formation and the 
activation of PGD synthase. Thus, the A12 PGJ2 -PPARy-1 pathway may have a signifi­
cant influence on bone formation upon mechanical loading. 
IV.2. Primary culture of osteoblasts 
The choice of using the primary osteoblasts culture came from the supposition 
that the human osteoblasts in culture will maintain the overall characteristics of hu­
man bone cells. In this method, the osteoblasts are derived from trabecular bone ex-
plants from patient undergoing hip arthroplasty (removed femoral head); the cells are 
allowed 4 to 6 weeks to reach confluence, and they are used at first passage. 
The utility of this method is somehow limited, the access to bone specimens 
not being continuous, the outgrowth time being rather long, and because of the high 
cost associated to the full usage of the cells at first passage. 
The limitations arise from the heterogeneity of the cultured cells (Matsuyama 
et al., 1990) and their age-dependent response (Sutherland et al., 1995) - osteoblastic 
cultures derived from older donors are likely to contain fewer osteoprogenitor cells, 
and represent more differentiated osteoblasts compared with those derived from 
younger donors (Zhou et al., 2008). 
We believe that the heterogeneity of the cultured cells has been overcome with 
the use of dexamethasone (as a glucocorticoid) and vitamin D (l,25(OH)2D3), both 
having a "levelling" effect in respect to the cell phenotype, acting as "osteoblastic in­
ducers" (Jorgensen et al., 2004). Moreover, the osteoblast response to specific stimuli 
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is present: the cells are capable of producing alkaline phosphatase induced by vitamin 
D, and mineralised nodules followed a Dexamethasone stimulation. 
The major prostaglandin receptors have been already proven to exist at human 
osteoblasts level (Sarrazin et al., 2001). The local production of the PGD2 through the 
lipocalin-type PGD2 synthase (L-PGDS) as well as the presence of both PGD2 recep­
tors, the DP and CRTH2, has been also established (Gallant et al., 2005) however it is 
considered that the endogenous production is low or absent in unstimulated condi­
tions. 
V1.3. Osteoblast proliferation 
A preliminary test (time-course) was necessary to estimate the differences be­
tween different timeframes of stimulation. We can confirm that we did not see any 
significant differences throughout the 24h to 96h stimulation with the PGD2 or DP/ 
CRTH2 agonists. Exogenous PGD2 and the agonist for CRTH2 receptor (DK-PGD2) 
decreased the proliferation compared to the unstimulated condition, but the effect 
seem to be restored at higher concentration. The effect however was more prominent 
for the PGD2 than for the specific DP/CRTH2 agonists, suggesting a third possible 
signalling mechanism. PGD2 appears to have the potential to signal via the cell surface 
receptors - DP, other PG receptor family members, or CRTH2 - via the nuclear recep­
tor PPARy, or to modify signalling by direct interaction with intracellular proteins 
such as NF-KB (NF-KB is a regulator of genes that control cell proliferation and cell 
survival) (Dussault & Forman, 2000a). 
On a 24h stimulation with the PGD2 or DP/CRTH2 agonists the proliferation 
decreased significantly for PGD2 and the CRTH2 agonist, suggesting that the effect 
could work through the CRTH2 receptor. 
We have confirmed that the PGD2 decreases the osteoblast proliferation in a 
dose-dependent manner using the PGD2 alone or in conjunction with the COX in­
hibitors. 
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For the DP agonist BW245C we did not see any significant change of prolifera­
tion either for the agonist alone, or when used with the COX inhibitors, suggesting 
that the DP receptor is not involved in signalling at this level. 
For the CRTH2 agonist used alone we see a decreasing trend-line up to 10 8M, 
but the effect seems to be restored when further increasing the concentration. When 
this agonist is used with Naproxen, this effect could be replicated but for a concentra­
tion of lO 9 (statistically significant) after which the control level is restored. When 
Diclofenac is used, we observe the same decreasing trend-line, more consistent as the 
concentration increases, but with no significant values. 
We have to mention that at micro-molar concentrations of 15d-PGj2, A12-PG)2, 
PGJ2, and PGD2 have been shown to activate the nuclear receptor PPARy (Forman et 
al., 1995); it seems plausible that PPARy may represent another mean for micro-molar 
concentrations of PGD2 metabolites to inhibit the proliferation. In contrast, a pro­
inflammatory (chemotactic) role for 15d-PGj2 at much lower ligand concentrations 
has been observed recently in eosinophils (Kobayashi et al., 2005). That could be ex­
plained through the binding of 15d-PG)2 to the CRTH2 receptor who is responsible for 
this effect (Sugimoto et al., 2005), but not through the binding to the DP receptor. 
The activation of PPARy by 15dPGj2 converts rodent osteoblastic cells to ter­
minally differentiated adipocytes and simultaneously suppresses the osteoblast phe-
notype and Cbfal expression and can inhibit proliferation (Maurin et al., 2005) prov­
ing that PPARy is implicated in gene regulation (Kliewer et al., 1997). However, 15d-
PGJ2 levels in vivo are reported to be several orders of magnitude too low to be con­
sidered as the endogenous mediator of PPARy activation (Powell, 2003). 
In the first phase, active proliferation is reflected by mitotic activity with ex­
pression of genes associated with cell cycling (e.g., histone) and growth (e.g., proto-
oncogenes c-myc, c-fos, and c-jun) (McCabe et al, 1995). Several other genes associ­
ated with formation of the extracellular matrix (type 1 collagen, fibronectin, and 
TGF$) are also actively expressed (Aronow et al., 1990) and then gradually down-
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regulated with collagen mRNA being maintained at a low basal level during subse­
quent stages of osteoblast differentiation. 
There is a difference to be underlined in the nature of the non-specific COX 
inhibitors. Naproxen is known to be also a ligand (agonist) for the PPARy (Jaradat et 
al., 2001). We note that Diclofenac is also a ligand for the PPARy, but having an an­
tagonistic role (Bishop-Bailey & Wray, 2003). 
Another phenomenon to account for is that the the PG and the PG agonists 
induce COX-2 expression in this system in parallel with the PG stimulation of cAMP 
production and is mediated probably via the phospholipase C pathway - a mechanism 
of feedback in regulating the COX-2 expression (Pilbeam et al., 1995). The auto-
amplification effect may be particularly important in cell cultures, where PGs are not 
rapidly degraded, and may account for the biphasic or recurrent induction of COX-2 
seen in some long-duration cultures. 
By using the PGD2 alone at different concentrations, we confirm the anti­
proliferative effect given by the growth inhibition (Fukushima, 1992). 
The transformation in plasma of PGD2 to 15d-PGj2 leads consequently to the 
activation of the PPARy responsible for the anti-proliferative effect, and possibly in­
creased its expression (Maurin et al., 2005). The known in vitro concentrations for the 
15d-PGj2 are in the micro-molar range (5-10 |JM) (Khan & Abu-Amer, 2003), while the 
endogenous concentrations are 0.1-lnM (Bishop-Bailey & Wray, 2003). 
By adding Naproxen to all conditions, and accounting for the errors, the 
measured effect for the proliferation in the presence of increasing concentrations of 
PGD2 was slightly decreasing with PGD2 at 10~7 M and 10 6 M having significant val­
ues. The same test using Diclofenac had a similar effect on proliferation, but the only 
significant concentration of PGD2 was 10~6 M. Diclofenac is responsible for decreasing 
the proliferation for SAOS cells, at concentrations of 15xl0 6 M (Kaspar et al., 2005), if 
this may be the case, that could explain the same effect for both COX inhibitors, in 
conjunction with the added PGD2 although the concentration of Diclofenac used in 
experiments was fixed at 10 6 M. 
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The controversial effects observed could be the result of multiple interactions, 
some related to the PGD2 receptors, and some related to signalling mechanisms in­
volving the PPARy. Besides the well-known anti-proliferative effects of the PPARy, 
some studies show that this nuclear receptor could be implicated in the development 
of tumours by PGJ2 and 15d-PGj2 induced proliferation of COX-2-depleted colorectal 
cancer cells at a nano-molar concentration, but reduced by these PGs at micro-molar 
concentrations (Chinery et al., 1999). Therefore, the proliferative/anti-proliferative 
effects of PPARy ligands are likely to be dependent on their intracellular concentra­
tions. It should be noted that PGs formed endogenously at submicromolar concentra­
tions are biologically more relevant in terms of regulating cell proliferation. Some 
authors (Yamazaki et al., 2002) showed that the effects of NSAlDs on rheumatoid 
synovial cells were not related to the inhibition of COX isozymes, but to the stimula­
tion of PPARy which can point to the fact that the inhibition of COX does not have 
necessarily anti-proliferative effects. 
The effect observed in activating the CRTH2 receptor (decreasing prolifera­
tion) may be due the indirect activation of arrestins (non-GPCR signaling) that might 
lead to MAP-kinase activation (Ulven & Kostenis, 2006). Also, the 15d-PGj2 can acti­
vate the MAP-kinase through an independent PPARy mechanism (Lennon et al., 
2002). 
We can conclude that effect of the PGD2 over the osteoblast proliferation has 
an overall inhibitory role probably acting through the CRTH2 receptor, however 
other mechanisms cannot be excluded. 
IV.4. Differentiation 
Immediately after the down-regulation of proliferation, proteins associated 
with the osteoblast phenotype are detected such as the alkaline phosphatase. With 
progression into the mineralisation stage, all cells become positive for alkaline phos­
phatase. 
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Osteoblasts synthesise and secrete type 1 collagen, glycoproteins such as os-
teopontin (rich in sialic acid; N- and O-linked oligosaccharides) and osteocalcin (con­
tains glutamic and aspartic acid residues), cytokines and growth factors into a region 
of unmineralised matrix (osteoid) between the cell body and the mineralised matrix. 
In addition, osteoblasts produce a specific membrane-bound molecule known as re­
ceptor activator of NF-KB ligand (Anderson et al., 1997). This factor is responsible for 
programming osteoclast differentiation and also functions as a dendritic cell survival 
element (Yasuda et al., 1998). 
The exogenous PGD2 at different concentrations alone or in the presence of 
Naproxen did not produce a significant effect on the differentiation. When Diclofenac 
was used, we can say that probably the only significant value (decreased differentia­
tion at 10 6M) is due to the high concentration of the PGD2 or due to some other 
mechanisms. 
In the series that contained the vitamin D, the PGD2 alone decreases the dif­
ferentiation in a dose-dependent manner, and the same effect is partially replicated by 
using Diclofenac (not significant), but not when Naproxen was used. 
For the test with DP/CRTH2 antagonists, without vitamin D, we did not see 
any effect given by the activation of CRTH2. A possible response was obtained for the 
activation of the DP receptor with the significant value of 10 6 for the PGD2 when we 
see a decreased level of alkaline phosphatase. Even if the trend-line could suggest a 
dose-response effect it is difficult to assess this because of the low number of donors. 
Considering the transformation of PGD2 into 15d-PGj2 in plasma, we can men­
tion again the parallel signalling of this prostaglandin in connection to the PPARy, 
but contrary to the literature, we did not see any inhibitory effect as mentioned by 
(Khan & Abu-Amer, 2003). The mechanism is similar to the one explaining the PPARy 
inhibiting effect for the proliferation, however in our case no significant modification 
has been seen, although the cells responded well when stimulated with vitamin D. 
Interestingly, some studies in vitro suggest that human osteoblasts respond to exoge­
nous vitamin D by decreasing their rate of proliferation, as well as increasing their ex­
pression of mRNA species encoding osteocalcin, bone sialoprotein-1, and RANKL (At­
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kins et al., 2007) probably preparing the osteoblast for the mineralisation stage. It is 
probably the transition that was detected when performed the tests in the presence of 
vitamin D, the stimulation with high concentration of PGD2 potentiating this effect 
by unknown mechanisms. 
PPARy is an important nuclear receptor family for adipocyte differentiation 
balancing the transformation between the osteoblasts and adipocytes since osteo­
blasts share the same origin with adipocytes in bone marrow cavity (Lecka-Czernik & 
Suva, 2006) that could explain the fatty marrow, accumulation of adipocytes in bone 
marrow, observed in the patients who manifest bone diseases such as osteoporosis. 
By stimulating the cells with PGD2 in presence of T0070907 (PPARy antago­
nist) we did noticed a drop in alkaline phosphatase expression, but with no significant 
values, suggesting that the inhibition of the differentiation might use the DP pathway 
or other signalling systems. 
We have to mention studies related to the origin of the harvested cells, indicat­
ing that primary osteoarthritis osteoblast-like cells (coming from patients with os­
teoarthritis) express higher alkaline phosphatase activity and osteocalcin release, both 
under basal conditions and with 1,25-dihydroxyvitamin D stimulation. They show de­
creased cAMP synthesis in response to human parathyroid hormone and prostaglan­
din E, in contrast to normal osteoblast cells, a result that could not be attributed to 
altered adenylate cyclase activity (George Hilal et al., 1998). Regarding the age of the 
patients, the literature suggests that is an age-dependent correlation to the decreased 
proliferation, osteoblastogenesis, differentiation and increased apoptosis for a test in­
volving human mesenchymal cells (Zhou et al., 2008). 
We can conclude that from our experiments without vitamin D, PGD2 has no 
effect over the differentiation except for PGD2 at 10 6 M used with Diclofenac. The 
same effect is seen when we activate the DP receptor only, suggesting a possible 
mechanism by activating this receptor, however the data is not conclusive. By block­
ing the PPARy receptor and stimulating the cells with PGD2 the measured alkaline 
phosphatase drops below the control level, implying that this receptor is not involved 
directly. The response is similar to the one observed when we stimulated the cells 
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with PGD2 in presence of Diclofenac, a possible antagonist of PPARy (Bishop-Bailey & 
Wray, 2003), but not in Naproxen's presence, suggesting that in fact the PPARy might 
have a positive effect over the differentiation of the osteoblasts. 
For the experiments performed in the presence of vitamin D, PGD2 decreased 
the differentiation dose-dependently. By using the Naproxen, we did not see any ef­
fect. When Diclofenac was used, we obtained a decreasing trend-line as the PGD2 
concentration increased, suggesting again the involvement of the PPARy in stimulat­
ing the differentiation. 
The PGD2 have an inhibitory effect over the human osteoblast differentiation, 
probably through the DP receptor activation. 
Vl.S. Matrix mineralisation 
Performing the first measurement of calcium for the PGD2 stimulated osteo­
blasts we observed that the prostaglandin had a stimulative effect over the matrix 
mineralisation, suggesting a dose-response effect, however without any significant 
values. 
In competitive tests of PGD2 at 10 9 M and the specific DP/CRTH2 antagonists 
BWA868C and CAY10471 respectively, no effect is seen, leading to the conclusion that 
the positive effect that PGD2 might have on the calcification is obtained through 
other mechanisms. 
Some publications relate to an altered phenotype of cultured osteoblasts who 
have elevated alkaline phosphatase and osteocalcin levels coming from patients with 
osteoartritis, but who have an impaired mineralisation as a consequence of an imbal­
ance in collagen lAl/collagen 1A2 triggered by TGF(3 (Couchourel et al., 2009). The 
possible change of the phenotype towards the adipocytes by activating the PPARy is 
not to be neglected, Naproxen being added to all conditions and 15d-PGj2 being pre­
sent in plasma as previously discussed. The absence of PGE2 by blocking non-
specifically the COX enzymes could also account for the absence of calcification 
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(Marks & Miller, 1988) although some suggest that the PGD2 has a bigger role in ma­
trix mineralisation than PGE2 (Asano et al., 2009) by having a stimulating action on 
Na inorganic phosphate transport through a MAP-kinase pathway (Asano et al., 2009). 
Suspecting a PPARy activation, we used T0070907, a highly specific antagonist 
of the human PPARy receptor at a concentration of 10 6M in conjunction with PGD2. 
The treatment seems to diminish the calcification, with T0070907/PGD2 at 10 8M 
having a significant value, suggesting that probably the PPARy is involved in the posi­
tive effects on mineralisation. 
The products of PGD2 metabolism can activate separately the DP/CRTH2 re­
ceptors, 15-deoxy-12'14-PGD2 and 12-PGD2 having for instance a higher affinity for the 
CRTH2, but the former being an agonist for the PPARy too, showing that DP and 
CRTH2 can be regarded as antagonistic receptors, CRTH2 mediating pro­
inflammatory and pro-stimulatory effects and DP limiting CRTH2 activation upon 
exposure to PGD2 on mast cells (Kostenis & Ulven, 2006). Moreover, some competi­
tive antagonistic effects could exist between the PGD2 receptors and the PPARy, as a 
result of a direct action of PGD2 or indirectly, by its metabolites. The difference be­
tween the rate of recycling of the two receptors on the cell surface could also play a 
role in the signalling (Gallant et al., 2007), the multiple interactions present changing 
the internalization rates by acting on arrestins. 
As a conclusion, we observed that the PGD2 might have a positive effect on 
human osteoblasts matrix mineralisation by acting on the PPARy directly or through 
the plasma degradation products of PGD2. 
V. Conclusions 
The study confirmed some of the data present in the literature like the effect 
of PGD2 on the proliferation and the differentiation, but brought contradictory in­
formation in regards to the calcification of the human cultured osteoblasts. Of course, 
the literature confirms that too, proving once more the controversial effects of the 
prostaglandins for the in vitro studies. 
It is becoming clear that we cannot separate the multiple interactions that 
might appear in the proposed system even though we can measure some of the ef­
fects. 
The PGD2 decreases the osteoblasts proliferation proliferation in a dose-
dependent manner alone or in conjunction with the COX inhibitors. We can conclude 
that effect of the PGD2 over the osteoblast proliferation has an overall inhibitor)' role 
probably acting through the CRTH2 receptor, however other mechanisms cannot be 
excluded. 
Exogenous PGD2 at different concentrations alone or in the presence of 
Naproxen did not produce a significant effect on the differentiation. By stimulating 
the cells with PGD2 in presence of PPARy antagonist we did not notice a significant 
response. PGD2 dose-dependently decreases the differentiation of osteoblasts in the 
presence of vitamin D. The lack of a clear response on the differentiation of the os­
teoblasts and the inhibitory effect obtained when vitamin D was used implied the ex­
istence of other mechanisms. 
The PGD2 has no significant effect over the matrix mineralisation through 
DP/CRTH2 activation. The mineralisation is decreased when blocking the PPARy re­
ceptor. This receptor is therefore involved in augmenting the calcification in this par­
ticular case. 
Perhaps the role of the PPARy becomes more clear on the calcification, but we 
cannot ignore many other mechanisms given by degradation of the main compound, 
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secondary signalling through different messengers or even delays in receptor recy­
cling. 
The added chemicals can also trigger different messaging systems and some of 
them could activate partially the DP/CRTH2 receptors. 
The human osteoblasts in culture, although presenting a certain heterogeneity 
are a valid replica of in vivo processes. The fact that the origin of the cultured cells 
come from the patients with osteoarthritis or from old patients with a certain pathol­
ogy of their bone apparatus may somehow impede over the consistency of the results, 
but this fact can be taken into account and judged accordingly. 
Perspectives 
The fact that the PGD2 could have an anabolic effect on different stages in the 
evolution of human osteoblasts is not to be neglected. 
More studies have to be performed in different conditions, with PPARy an­
tagonists to eliminate possible contrary effects on assessing the effects of the PGD2. 
The number of experiments could also lead to interesting results, having several lines 
of cultured cells giving a more homogenous answer. The downfall of this is the cell 
culture timeframe and the supply with the bone explants. 
It would be maybe worthwhile to test the line of cells coming from the same 
patient for all the three assays, proliferation, differentiation and mineralisation, this 
indicating a more consistent evolution of the cell line. Also, it would be interesting to 
correlate the cell line with the age of the patient, sex, general habits (alimentation, 
sports, smoking) and with the disease of the patient. 
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